Dismantling the aberrant signaling network in chronic lymphocytic leukemia: PP2A and SHP-1 as promising targets for drug discovery by Pagano, Mario Angelo Primo
  
 
University of Padova 
Department of Pharmaceutical and Pharmacological Sciences 
 
DOCTORAL COURSE IN PHARMACOLOGICAL SCIENCES 
CURRICULUM MOLECULAR AND CELLULAR PHARMACOLOGY 
XXIX SERIES 
 
 
 
 
DISMANTLING THE ABERRANT SIGNALING NETWORK IN 
CHRONIC LYMPHOCYTIC LEUKEMIA:  
PP2A AND SHP-1 AS PROMISING TARGETS  
FOR DRUG DISCOVERY 
 
 
 
Coordinator: Prof. Piero MAESTRELLI 
Supervisor: Prof. Sergio BOVA 
Co-Supervisor: Prof. Anna Maria BRUNATI 
 
 
    PhD candidate: Mario Angelo Primo PAGANO 
 
      
 2 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
 
 
CONTENTS 
 
LIST OF ABBREVIATIONS ....................................................................................................... 6 
One and three-letter codes of amino acids ................................................................................ 6 
ABSTRACT (English) .................................................................................................................. 9 
ABSTRACT (Italiano) ................................................................................................................ 10 
INTRODUCTION ....................................................................................................................... 11 
CHRONIC LYMPHOCYTIC LEUKEMIA ............................................................................... 12 
Etiology, Diagnosis and Staging .......................................................................................... 12 
Cellular, molecular and functional features of CLL ............................................................ 13 
Mutational status of IgVH ............................................................................................ 15 
ZAP70 and CD38.......................................................................................................... 17 
The CC chemokine family ............................................................................................. 18 
Genetic lesions .............................................................................................................. 18 
Signaling in CLL cells: overview ........................................................................................ 20 
Current pharmacologic treatments .................................................................................. 22 
Kinase inhibitors in the treatment of CLL ....................................................................... 23 
Lyn and its substrates: anti-apoptotic strategy of CLL cells ................................................ 24 
PROTEIN PHOSPHATASE 2A: MASTER REGULATOR OF VIRTUALLY ALL CELLULAR 
PROCESSES ............................................................................................................................ 27 
PP2A: structure .................................................................................................................... 27 
PP2AC: the catalytic subunit ............................................................................................ 28 
PP2AA: the structural subunit ........................................................................................... 28 
PP2AB: the regulatory subunit.......................................................................................... 29 
B family (PR55) ............................................................................................................ 29 
B’ family (PR61) ........................................................................................................... 29 
B’’ family (PR72) .......................................................................................................... 30 
B’’’ family ..................................................................................................................... 30 
PP2A: function ..................................................................................................................... 30 
PP2A as a tumor suppressor ............................................................................................. 31 
PP2A and apoptosis .......................................................................................................... 32 
PP2A: regulation .................................................................................................................. 33 
Post-translational modifications ....................................................................................... 33 
Physiological modulators: cellular inhibitors ................................................................... 33 
I1PP2A.......................................................................................................................... 33 
I2PP2A (SET) ............................................................................................................... 34 
CIP2A ........................................................................................................................... 35 
Physiological modulators: cellular activators .................................................................. 35 
Ceramides ..................................................................................................................... 35 
Non-physiological inhibitors ............................................................................................ 36 
Okadaic acid (OA) ........................................................................................................ 36 
Forskolin ....................................................................................................................... 36 
 4 
 
Fingolimod (FTY720) ................................................................................................... 37 
SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE 1 (SHP-1) ......................... 40 
SHP-1: structure ................................................................................................................... 41 
SHP-1: function ................................................................................................................... 42 
SHP-1 activators: angiokinase inhibitors doing a front flip? ............................................... 44 
RATIONALE OF THE STUDY ................................................................................................. 47 
EXPERIMENTAL SECTION .................................................................................................... 49 
Nintedanib directly activates SHP-1 in the cytosol of CLL cells ............................................ 50 
Nintedanib induces activation of caspase-8 and PP2A by decreasing tyrosine 
phosphorylation in CLL cells .................................................................................................. 55 
Apoptosis of the CLL cells can be induced by indirect activators of SHP-1 ........................... 60 
MP07-66 potentiates the pro-apoptotic effect of nintedanib ................................................... 62 
Discussion ................................................................................................................................ 65 
MATERIALS AND METHODS ................................................................................................ 70 
MATERIALS ............................................................................................................................ 71 
METHODS............................................................................................................................... 71 
Ethics Statement ................................................................................................................... 71 
Patients, cell separation and culture conditions ................................................................... 71 
Cell lysis and subcellular fractionation ................................................................................ 72 
Immunoprecipitation of SHP-1 ............................................................................................ 72 
SHP-1 activity assay ............................................................................................................ 72 
[32P]-phospho band 3 preparation ....................................................................................... 73 
PP2A activity assays ............................................................................................................ 73 
Casp8 activity assay ............................................................................................................. 73 
Apoptosis assays .................................................................................................................. 73 
Western blotting ................................................................................................................... 74 
Cell transfection ................................................................................................................... 74 
In vitro tyrosine kinase assays ............................................................................................. 74 
Statistical analysis ................................................................................................................ 75 
REFERENCES ............................................................................................................................ 76 
 
  
 5 
 
 
  
 6 
 
LIST OF ABBREVIATIONS 
 
One and three-letter codes of amino acids 
 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid  
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
X  Any amino acid 
 
 7 
 
Abbreviations of protein factors 
 
SFK = Src Family Kinases 
Lyn = Yamaguchi sarcoma viral related oncogene  
APRIL = A Proliferation-Inducing Ligand 
ATM = Ataxia Teleangectasia Mutated 
BAD = Bcl-2 Associated Death promoter 
BAFF = B-cell Activating Factor 
Bcl-2 = B cell lymphoma gene 2 
BCR= Recettore a cellule B 
Bid =BH3-interacting domain death agonist 
BLNK = B-cell Linker 
BMSC = Cellule stromali midollari 
BSA = Albumina di siero bovino 
Btk = Bruton tirosina chinasi 
CARD11 = Caspase Recruitment Domain 11 
CD19 = Cluster of Differentiation 19 
CD38 = Cluster of Differentiation 38 
CD40L = Ligando di CD40 
Csk = C-terminal Src kinase 
CIP2A = Cancerous Inhibitor of PP2A 
ERK = Extracellular signal Regulated Kinase 
FADD = Fas-Associated Death Domain 
FLIP= FLIce-Inhibitory Protein 
GSK-3ß = Glycogen synthase kinase 3, ß isoform  
HEAT = Huntington Elongation factor 3/pr65 A TOR  
Hsp90 = Heat shock protein – 90 kDa 
IL = Interleukin 
ITAM = Immunoreceptor Tyrosine-based Activation Motif  
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ABSTRACT (English) 
Reversible  protein  phosphorylation  is  a  fundamental  post-translational  
modification  by  which  virtually all cellular events are regulated, enabling cells to 
properly respond to intra- and extracellular  cues.  Protein  kinases  and  protein  
phosphatases  are  the  principal  factors  involved  in  this  in  this  dynamic process 
and are placed at the different levels of cellular signalling, and, albeit traditionally  
considered as functionally opposed to one another, not rarely act in an interplay to 
finely orchestrate and appropriately drive signal transduction. The imbalance of 
their expression and function affects the cell life and fate, which frequently 
underlies the onset and progression of a plethora of diseases.   
B cell chronic lymphocytic leukemia (CLL), the most common leukemia in the 
Western world, is no  exception to this paradigm, many studies having highlighted 
a crucial role of kinases in the sustained signals from the signalosome downstream 
of the B cell receptor (BCR), and having led to the development of the promising 
second-line drugs, but also the blockade of a number of phosphatases underlying 
pro-survival and anti-apoptotic signals. In this regard, Protein Phosphatase 2A 
(PP2A) and the Src homology 2 domain-containing phosphatase 1 (SHP-1) exhibit 
a marked functional inhibition in this disease, which can be properly circumvented 
by a pharmacological approach, thereby inducing apoptosis of cancer cells. 
Nintedanib and MP-0766, a drug  acting as an angiokinase inhibitor and a new 
fingolimod analogue devoid of immunosuppressive  action, activating respectively 
SHP-1 and PP2A have enabled for the discovery of a signalling axis  that when 
activated provokes massive cell death, and might provide a new paradigm for the 
treatment  of CLL, which now endorses kinase inhibitors.     
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ABSTRACT (Italiano)  
La fosforilazione proteica è una fondamentale modificazione post-traduzionale che 
regola virtualmente tutti i processi cellulari, permettendo alla cellula di rispondere 
a stimoli intra- ed extracellulari. Le protein chinasi e le protein fosfatasi sono i 
fattori principali coinvolti in questo processo dinamico e si localizzano a diversi 
livelli del signaling cellulare, e, sebbene tradizionalmente considerate opposte le 
une alle altre sotto il profilo funzionale, non raramente compartecipano per 
finemente modulare e opportunamente dirigere la trasduzione del segnale.  
Uno squilibrio di espressione e/o funzione di questi fattori si riflette sulla vita e il 
destino della cellula, cosa che frequentemente è alla base dell’insorgenza nocnhé 
l’evoluzione di un gran numenro di patologie. La leucemia linfatica cronica  a 
cellule B (B Chronic Lymphocytic Leukemia, CLL), la più comune leucemia in 
occidente, non fa eccezione a tale paradigma e, sebbene la ricerca per lo più si è 
concentrata sull’anomala attività di diverse protein chinasi con lo sviluppo di 
promettenti farmaci di seconda linea, sempre più di frequente viene confermata 
l’ipotesi che la sopravvivenza e la resistenza all’apoptosis delle cellule tumorali 
dipende anche dalla ridotta espressione o funzionalità delle protein fosfatasi. A 
questo riguardo, la protein fosfatasi 2A (Protein Phosphatase 2A, PP2A) e la 
fosfatasi 1 contenente domini Src homology 2 (Src Homology 2 domain-containing 
phosphatase 1 (SHP-1) in questa patologia si dimostrano funzionalmente inibiti, 
ma che, quando opportunamente attivate farmacologicamente, inducono morte 
delle cellule tumorali. 
Nintedanib, un farmaco che agisce come inibitore “angiochinasico”, e MP-0766,  
un nuovo analogo del fingolimod privo di azione immunosoppressiva, si sono 
dimostrati in grado di attivare SHP-1 e PP2A rispettivamente, permettendo inoltre 
di individuare un asse di signaling cellulare che provoca la morte di celle cellule 
leucemiche, potenzialmente rappresentando un nuovo paradigma per il trattamento 
della CLL, che ad oggi privilegia gli inibitori chinasici.  
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CHRONIC LYMPHOCYTIC LEUKEMIA  
Etiology, Diagnosis and Staging 
It is the most common form of leukemia diagnosed in adults in Western countries, 
the median age at diagnosis being 72 years with an incidence of 4.2:100 000/year, 
which increases to >30:100 000/year in patients aged over 80 years (Eichhorst et 
al, 2015). As to the etiology of CLL, inherited genetic susceptibility for CLL seems 
to play a major role (Slager et al, 2013; Yang et al., 2015) although other possible 
caused including ionizing radiation (Linet et al., 2007) or the use of pesticides 
(Cocco et al., 2013) cannot be ruled out.  
CLL is a dynamic disease with a highly heterogeneous clinical course varying from 
the stable, long-lasting indolent form to rapidly progressive disease and 
death (Chiorazzi et al., 2005; Stevenson and Caligaris-Cappio, 2004), one third 
remaining asymptomatic for years (Hallek et al., 2008), whereas others may 
experience an aggressive clinical course with a rapid increase in diseased cells in 
the blood and require very intensive treatment (Elphee, 2008). 
The majority of CLL patients are asymptomatic, being accidentally diagnosed as a 
result of a routine blood test, which shows absolute lymphocytosis defined as more 
than 5000 cells/μL. 10% of patients present with symptoms consisting in 
unexplained fevers, unintentional body weight loss or night sweats, most of them 
having enlarged and palpable lymph nodes on examination, accompanied 20 to 
50% of the cases by hepatosplenomegaly (Nabhan and Rosen, 2014). CLL cells 
then undergo further characterization by immunophenotyping, molecular genetics 
and cytogenetics to properly establish diagnosis and prognosis (see below).  
Two clinical staging systems are used for predicting median survival, which 
classify patients on the basis of blood parameters and clinical signs such as 
hemoglobin concentration and thrombocyte count (Binet), 
lymphocyte/thrombocyte count and the presence or absence of 
lymphadenopathy/organomegaly (Rai) (Table 1) (Binet et al., 1981; Rai et al., 
1975). The Binet staging system is widely used in Europe, whereas in the United 
States, the Rai system is more commonly employed.  
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Table 1. Rai and Binet Staging Systems 
Rai    
Stage Risk Clinical Features Overall Survival, yrs 
0 Low Lymphocytosis in peripheral blood and 
bone marrow only  
>10 
I/II Intermediate Lymphadenopathy ± hepatosplenomegaly 7 
III/IV High Anemia ± thrombocytopenia  <4 
    
Binet    
Stage Risk Clinical Features Overall Survival, yrs  
A Low <3 areas of lymphadenopathy 12 
B Intermediate >3 areas of lymphadenopathy 7 
C High Anemia, thrombocytopenia, or both 2-4 
 
Cellular, molecular and functional features of CLL  
Chronic Lymphocytic Leukemia (CLL) is a clonal lymphoproliferative disorder 
characterized by the slow accumulation of small, mature B lymphocytes in the 
peripheral blood, bone marrow and in the secondary lymphoid organs (spleen and 
lymph nodes). These leukemia cells express specific surface markers (so-called 
Cluster Differentiations, CD) such as CD19, CD5 and CD20, CD23, typicaly 
lacking CD22 and CD52 (Figure 1) with weak expression of surface 
immunoglobulins compared to normal B cells as established by flow cytometry and 
immunophenotyping of the peripheral blood (Nabhan and Rosen, 2014; Matutes 
Figure 1. Typical surface markers of CLL B lymphocytes as described in 
http://www.campath.com/UnderstandingCLL/CellMarkers.html 
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and Polliack, 2000; Eichorst et al., 2015). CLL cells undergo spontaneous 
apoptosis in vitro, from which they are protected when cultured in the presence of 
dendritic or nurse-like cells (NLCs), among others, NLCs being a subset of blood 
monocytes in CLL patients (Tsukada et al., 2002). This finding supports the 
hypothesis that the resistance to apoptosis of CLL cells, in addition of intrinsic 
defects, also depends on extrinsic factors, especially in the microenviroment of 
secondary lymphoid tissues from where these cells originate and mature (Herreros 
et al., 2008). Figure 2 shows the high complexity of such interactions (ten Hacken 
and Burger, 2016).  
Figure 2. Various cellular and molecular components of the CLL microenvironment. Nurselike 
cells (NLCs); B Cell Receptor (BCR); Follicular Dendritic Cells (FDCs); Mesenchimal Stromal 
Cells (MSCs) 
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CLL cells in the blood smear are small, mature lymphocytes with a narrow border 
of cytoplasm and a dense nucleus with clumped chromatin. These cells may 
undergo partial breakdown during slide preparation because of the fragile nature of 
these cells (“Gumprecht shadows”, Figure 3). 
Among the causes of the heterogeneity of the clinical course of the disease specific 
molecular alterations have been established, and namely the mutation of the genes 
coding for the Immunoglobulin Variable region Heavy chain (IgVH) and the level 
of expression of CD38 and Zeta chain Associated Protein kinase 70 (ZAP70) 
(Hamblin et al., 2007). 
 
Mutational status of IgVH 
Signal transduction in B cell is mediated by the B Cell Receptor (BCR), a 
transmembrane protein complex formed by an immunoglobulin (Ig) placed on the 
cell’s outer surface connected to a network of kinases and phosphatases that tune 
and amplify its activation. The interaction with antigens are central to BCR’s 
controlling B-cell fate and directing cell maturation, survival, anergy as well as the 
production of antibodies in plasma B cells (Reth and Nielsen, 2014; Dal Porto et 
al, 2004). The heavy and light chains of the Ig are the products of random 
rearrangement of immunoglobulin gene segments, which results in the highly 
diverse repertoire of Igs. On the basis of the degree of somatic mutation of the 
Figure 3. This smear shows the presence of four small neoplastic lymphocytes and one 
“Gumprecht shadow” (arrowhead). 
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IgVH genes, CLL patients can be classified into the 2 subgroups, unmutated CLL 
(U-CLL) or mutated CLL (M-CLL), depending on the strong or weak sequence 
homology with the sequence of the germ-line gene. U-CLL patients statistically 
have a poor prognosis with an aggressive course and often short survival, in 
contrast with those carrying IgVH mutations, who have a slow course and much 
longer life expectancy (Hamblin et al., 1999). The mutational status affects the 
BCR responsiveness to antigen stimulation, U-CLL patients expressing 
multireactive and non-selective BCRs binding a wide range of molecules present 
in the surrounding microenvironment, resulting in a sustained activation of BCR-
dependent signals and a more aggressive disease (Burger and Chiorazzi, 2013). 
Figure 4 shows the organization of the “signalosome” on the inner leaflet of the 
plasma membrane of a CLL B cell functionally connected to the two mutational 
forms of BCR. U-CLL cells respond to a greater variety of antigens, the signals 
downstream of the BCR being reiforced by the contribution of the tyrosine kinase 
ZAP-70 and the multifunctional receptor CD38. 
Figure 4. Differences between M-CLL and U-CLL signaling pathways (from ten Hacken and 
Burger, 2016).  
 17 
 
However, since the analysis of gene sequences underlying the status of IgVH 
mutation is laborious, reliable alternative markers are CD38 and ZAP-70, or the 
chemokines CCL3 and CCL4 . 
 
ZAP70 and CD38 
ZAP70 is a non-receptor tyrosine kinase normally expressed in T cells, Natural 
Killer (NK) cells, activated but not quiescent B cells. In fact, the majority of B 
lymphocytes expressing not this protein, but the tyrosine kinase named Syk. It is 
believed that its presence in B cells is linked to antigenic stimulation. 
This protein is associated with the CD3 receptor of T lymphocytes, and is involved 
in signals downstream of the T Cell Receptor (T Cell Receptor) following antigen 
engagement (Wang et al., 2010). ZAP70 in CLL cells seems to play a similar 
function in the signals mediated by the BCR. Because ZAP70 is expressed in U-
CLL cells, it is also used as a molecular marker to distinguish the mutational status 
of CLL cells. In fact, patients with ZAP70 being expressed in more than 20% of 
CLL cells, are more likely to experience an aggressive course of the disease. In 
addition, U-CLL cells  expressing ZAP70 are more sensitive to chemokine (C-C 
motif) Ligand 19 (CCL19),  CCL21 and chemokine (C-X-C motif) Ligand 12 
(CXCL12), which stimulate migration and cell proliferation (Burger and Chiorazzi, 
2013). 
CD38 is a glycoprotein also known as cyclic ADP ribose hydrolase, which is found 
on the surface of many immune cells (Deaglio et al., 2006). It promotes cell 
proliferation by enhancing signals mediated by the BCR upon interaction with 
CD31, which is expressed on the surface of endothelial cells, among others 
(Deaglio et al., 2006). In addition to the proliferative response, emerging evidence 
indicates that CD31/CD38 interaction is also followed by migration and homing, 
suggesting a potential role for CD38 in directing CLL cells to specific 
microenvironments (Deaglio et al., 2010). Although CD38 was the first marker 
thought to be be closely related to the mutation status of IgVH genes, it was later 
proven that instead these two biological parameters are independent prognostic 
 18 
 
factors (Hamblin et al., 2002). On the other hand, CD38 is also an important 
complementary prognostic marker, generally related to a more aggressive clinical 
course (Malavasi et al., 2011). 
 
The CC chemokine family 
The chemokines named CCL3 and CCL4, also called Macrophage Inflammatory 
Protein (MIP)-1α and -1β, respectively, are chemokines of the CC family, inducible 
in adaptive immune responses of cells of hematopoietic origin such as 
macrophages, B and T lymphocytes and dendritic cells. Plasma levels of CCL3 are 
indicative of an aggressive clinical course in CLL. Previous studies conducted on 
co-cultures of CLL cells with monocytes acting as NLCs have shown that the 
activation of the BCR-depending cascades induces a marked synthesis and 
secretion of CCL3 and CCL4, and, as expected, the use of inhibitors of players 
downstream of the BCR greatly reduces the levels of CCL3 and CCL4 (Burger et 
al, 2009). As to the actual contribution of CCL3 in the pathogenesis of the disease, 
it is hypothesized that the secretion of this chemokine serves to attract additional 
cells such as T lymphocytes, NLCs and stromal cells in the microenvironment, thus 
creating a favorable environment for survival of leukemia cell clones (Burger and 
Chiorazzi, 2013; de Weerdt et al., 2013). 
 
Genetic lesions 
There are several types of genetic lesions in CLL, which also represent prognostic 
markers of CLL (Rossi et al., 2013; Hallek, 2013). Among the genetic alterations, 
there are 
• 13q14 deletion, present in more than 50% of patients, which also underlies the 
development of additional mutations in B cell clones; 
• mutation of the NOTCH1 gene, coding for a transmembrane protein that acts 
as a ligand-dependent transcription factor and is involved in the processes of 
differentiation, proliferation and apoptosis through cell transcriptional 
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activation of other genes such as MYC, TP53 and molecules of the NF-kB 
pathway;  
• mutations and deletions that cause degradation of BIRC3, gene implicated in 
the negative regulation of MAP3K14, which is the main activator of the non-
canonical NF-kB signaling pathway; 
• missense mutations of the SF3B1 gene, which is a basic component in the 
splicing process. The mutations in this gene are found in patients showing 
refractoriness to therapy (~ 15-20% of cases); 
• mutations of MYD88, a factor participating in the response of Toll-like 
receptors, which causes an increased survival due to cell to constitutively 
activated signal pathway mediated by NF-kB; 
• deletions, or somatic mutations such as missense mutations in exons 5-8 of the 
TP53 gene will cause the inactivation of the protein product, which is a nuclear 
factor involved in the regulation of apoptotic response upon DNA damage;  
• mutations of the Ataxia Telangiectasia Mutated (ATM) gene, which encodes a 
protein kinase that phosphorylates and activates p53 in response to damage to 
the DNA double helix. This injury causes the inactivation of ATM in only 30% 
of the cases. 
The lesions of the ATM and TP53 genes confer resistance to chemotherapy to 
CLL cells, since both genes are involved in the process of apoptosis. Besides, 
these deletions are associated with patients with U-CLL, who have a poor 
prognosis. 
• Trisomy 12 has been shown in 25% of U-CLL patients. This chromosome 
harbors the murine double minute 2 (MDM-2) gene, the product of which is an 
important regulator of the tumor suppressor gene TP53. Its overexpression 
leads to functional inactivation of the p53.  
• Deletions of chromosome 6, present in about 6% of cases, causing minor 
events related to intermediate prognosis. 
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Signaling in CLL cells: overview 
Reversible protein phosphorylation is a fundamental post-translational 
modification by which virtually all cellular events are regulated, enabling cells to 
properly respond to intra- and extracellular cues. The crucial players involved in 
this dynamic process are protein kinases and protein phosphatases, which are 
placed at the different levels of cellular signalling, and, albeit traditionally 
considered as functionally opposed to one another, not rarely act in an interplay to 
finely orchestrate and appropriately drive signal transduction (Johnson, 2009). The 
significance of both classes of enzymes in the cell life and fate is mirrored by the 
effects of their dysregulation, whether related to altered expression or activity, 
which frequently underlies the onset and progression of a plethora of diseases 
(Lahiry et al., 2010; Julien et al., 2011). CLL is no exception to this paradigm, a 
high level of intracellular phosphorylation being mediated by the abnormal activity 
of several kinases downstream of the B cell receptor (BCR), such as Lyn (Contri 
et al., 2005), Syk (Gobessi et al., 2009), PKC (Ringshausen et al., 2002), 
phosphoinositide 3-kinase (PI3K) (Plate, 2004), mitogen-activated protein kinase 
(MAPK) p38 (Sainz-Perez et al., 2006), resulting in a ligand-independent BCR 
signaling, also defined tonic signaling (Monroe, 2006). The peculiar structural and 
functional features of the BCR in CLL, which are related to the presence or absence 
of somatic mutations of the IgVH genes, often associated with atypical expression 
of ZAP-70, dysregulate the downstream signaling pathways, directly contributing 
to the onset and progression of the disease (Lanham et al., 2003; Rassenti et al., 
2004). Importantly, this has also led to new promising therapeutic approaches that 
interfere with aberrant kinase activities and are now employed in clinical practice 
(Figure 2, also see below). Whilst the role of dysrgulated kinase activities has been 
ascertained, accumulating evidence is consistent with the hypothesis that the 
abnormal signal transduction is also the result of the lack of a proper 
counterbalance mediated by a number of phosphatases, whose expression or 
activity is altered in CLL cells. For instance, PTEN (Zou et al., 2015), PTPROt 
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(Motiwala et al., 2007), PHLPP1 (Suljagic et al., 2010) and SHIP1 (Cui et al., 2014) 
exhibit significantly decreased expression, leaving tonic pro-survival signalling 
intact, whereas PTPN22, which acts as a positive regulator of anti-apoptotic signals 
by hampering the negative regulation of BCR-dependent signalling pathways, is 
overexpressed (Negro et al., 2012). By contrast, Protein Phosphatase 2A (PP2A) 
(Perrotti and Neviani, 2008) and the Src homology 2 domain-containing 
phosphatase 1 (SHP-1) (Tsui et al., 2006) are expressed in CLL at levels 
comparable to normal B cells, but are functionally dysregulated by a variety of 
mechanisms, which include phosphorylation, interaction with cellular partners and 
location and are chiefly mediated by the Src Family Kinase (SFK) Lyn (Zonta et 
al., 2015; Tibaldi et al., 2011). In this scenario, not only this imbalance, but also a 
direct connection between kinases and phosphatases, with vicious cycles that 
establish aberrant signalling axes (Zonta et al., 2015) might be the new perspective 
for the identification of novel drug targets.  
 
 
Figure 5. Factors taking part in aberrant BCR-dependent signaling and targeted by specific 
agents, which represent a new strategy in the treatment of CLL (from Hallek, 2013). 
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Current pharmacologic treatments 
Patients with early-stage (Binet stage A and B without active disease; Rai 0, I and 
II without active disease) do not experience a survival advantage if they undergo 
chemotherapy (Dighiero et al., 1998), the standard approach being a watch-and-
wait strategy. In contrast, treatment should only be initiated in patients with 
symptomatic, active disease (Binet stage A and B with active disease or Binet stage 
C; Rai 0 – II with active disease or Rai III – IV). Standard front-line treatment in 
physically ﬁt patients consists of ﬂudarabine, cyclophosphamide and rituximab 
(FCR), which has been shown to improve overall survival (Hallek et al., 2010), 
though being associated with severe infections in fit elderly patients when 
compared to bendamustine (a purine analog like fludarabine) and rituximab. Other 
purine analogs such as cladribine (Robak et al., 2010) or pentostatin (Kay et al., 
2007) have shown similar activity. In older patients with relevant co-morbidity and 
without TP53 deletion/mutation, progression-free survival has been observed by 
combining chlorambucil and an anti-CD20 antibody (rituximab, ofatumumab or 
obinutuzumab) when compared with monotherapy and is therefore the standard 
approach  (Goede et al., 2014; Hillmen et al., 2013).  
Patients with TP53 deletion/mutation should be treated with novel agents (the 
Bruton’s tyrosine kinase inhibitor ibrutinib or the combination of the PI3K inhibitor 
idelalisib with rituximab), since they have a poor prognosis even after FCR therapy 
(Hallek et al., 2010), either as a front line-therapy or an approach to treat relapses. 
An allogeneic hematopoietic stem-cell transplantation may be taken into 
consideration in fit patients responding to kinase inhibitors (Dreger et al., 2014).  
As to relapse and refractory disease, asymptomatic CLL patients should take no 
therapy for a long period of time. First-line treatment may be repeated if the relapse 
or progression occurs at least 24–26 months after chemoimmunotherapy and if 
TP53 deletion/mutation was excluded, whereas relapse occurring within 24–36 
months after chemoimmunotherapy, or the lack of responsiveness to any therapy 
requires a change in the therapeutic (Eichorst et al., 2015). Treatment options 
include: 
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 BCL2 antagonists, such as ABT-199, alone or in combination within a clinical 
study (Roberts et al., 2016) 
 Bruton’s tyrosine kinase inhibitor ibrutinib (Byrd et al., 2014) 
 PI3K inhibitor idelalisib in combination with rituximab (Furman et al., 2014). 
 
The drugs used in clinical practice as described above are only few of the potential 
agents that might be approved for CLL treatment, especially if we consider how 
complicated the network of signals generated by the many factors just beneath the 
plasma membrane of a CLL cell is (Figure 5). In this regard, as confirmed by the 
current second-line approach, the most interesting and promising molecules are the 
kinase inhibitors. 
 
Kinase inhibitors in the treatment of CLL 
As described above, there are kinase inhibitors that have been approved as second-
line therapy in CLL patients. A few of them are described below and include the 
already mentioned ibrutinib and idelalisib, which are the most effective and 
currently utilized in the treatment of this disease. (also see Figure 5, where various 
agents targeting components of the BCR signaling network are shown, although 
not yet approved for therapy or already shown scarcely efficacious if administered 
alone). 
 
Dasatinib. It is a second-line drug used for the treatment of chronic myeloid 
leukemia (CML) (Keating, 2017). It can also inhibit Src  Family Kinases (SFKs), 
such as Lyn, and Btk. Its application should be considered not as a single-agent 
therapy in CLL but in combination to sensitize tumor cells to fludarabine-mediated 
apoptosis (Aguillon et al., 2007). 
Ibrutinib. Irreversible inhibitor of Btk, it barely induces apoptosis of CLL in vitro. 
Ibrutinib can counteract the protective effect of CD40L, BAFF, TNF-α, IL-6, and 
IL-4 (Herman et al., 2011), also preventing the adhesion induced by anti-IgM 
 24 
 
antibodies, and the adhesion and migration of cells in response to chemokines (de 
Rooij et al., 2012). It has been to be able to induce the release of CLL cells from 
lymph nodes and bone marrow, considering the short rise in the lymphocyte count 
in the peripheral blood occurring following therapy, where they are no longer 
protected by the microenvironment, becoming prone to apoptosis (Chang et al., 
2013). Ibrutinib has been tested not only as a single agent but also in combination 
therapy (Byrd et al., 2014). 
 
Fostamatinib. It is a prodrug, its active metabolite being R406 and acting as a Syk 
inhibitors. It has also been studied for the treatment of autoimmune diseases such 
rheumatoid arthritis. In vitro fostamatinib, by inhibiting Syk, jeopardizes the 
viability of CLL cells, which cannot be rescued even when stimulated with anti-
IgM antibodies or placed in co-cultures with the NLCs. It exhibits synergy with 
fludarabine (Herman et al., 2013). 
 
Idelalisib. Also termed GS-1101 or CAL-101, it selectively inhibits the PI3Kδ 
p110δ isoform in vitro, thereby inducing apoptosis of CLL, and reducing the 
migration by blocking the signals generated by CXCL12 and CXCL13. It also 
shows fewer cytotoxic effects on NK cells when compared with non-selective 
inhibitors of PI3K (α, β, δ, γ) (de Weerdt et al., 2013). 
 
Lyn and its substrates: anti-apoptotic strategy of CLL cells 
One approach aimed at the discovery of new therapeutic targets in CLL is to 
explore the intracellular pathways responsible for modulating the proliferation 
and/or apoptotic rate of CLL cells. The extracellular cues that are sensed by the 
BCR in concert with other co-receptors need to be translated by intracellular 
switches, most of which are protein kinases, as described above. In the last ten 
years, the Src Family Kinase (SFK) Lyn has emerged as a factor central to 
sustaining the cancer phenotype of CLL cells and orchestrating the aberrant 
signaling network downstream of the BCR. In fact, it is the first protein kinase to 
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transduce the signal from BCR by phosphorylating the Immunoreceptor Tyrosine-
based Activation Motifs (ITAMs) placed on Igα / Igβ chains of the BCR, thus 
triggering the recruitment of other kinases and adapter molecules downstream, such 
as Syk, PLCγ2, PI3K, Btk, Vav and BLNK, which form the "signalosome". This 
multiprotein complex propagates the signals downstream and activates the 
signaling pathways that support proliferation, and/or survival through the 
activation of anti-apoptotic mechanisms (Contri et al., 2005; Tibaldi et al, 2011). 
In addition to a “positive” role, Lyn has also found to exert a “negative” action, by 
phosphorylating the inner tail of CLL surface marker CD5 and thus recruiting the 
tyrosine phosphatase SHP-1, which contributes to the anti-apoptotic signals by 
dephosphorylating specific targets such as Vav1 (Tibaldi et al, 2011; also see 
below). Yet, Lyn has been shown to be located not only at the plasma membrane, 
as expected, but also in the cytosol as a member of a multiprotein complex 
associated with HSP90, where it is maintained constitutively active, thus 
explaining the high level of tyrosine phosphorylation observed in this compartment 
of CLL cells (Trentin et al., 2008). The discovery illustrated above also spurred 
new research into the nature of possible Lyn’s cytosolic substrates with a view to 
extend the repertoire of new therapeutic targets of this disease, especially in the 
light of the disappointing results in managing Lyn-targeting drugs, such as 
dasatinib (McCaig et al, 2011; Kater et al., 2014). In this regard, the first evidence 
of how Lyn’s dysregulated expression, activity, and localization mediate resistance 
to apoptosis in CLL by affecting the phosphorylation status of a specific substrate 
in the cytosol emerged through the identification of procaspase-8. In fact, the 
phosphorylation at Y380 was shown to result in the dimerization of the caspase 
zymogen, blocking the so-called extrinsic pathway of apoptosis, whereas the use 
of SFK inhibitors abolished the phosphorylation of this initiator caspase, inducing 
its activity and initiating the apoptotic cascade (Zonta et al., 2014). Interestingly, 
by using both dasatinib and other SFK inhibitors, it was observed that not only 
tyrosine phosphorylation decreased, thus bringing about cell death by a caspase-
dependent mechanism, but also caused a drastic drop of the phosphorylation of 
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specific serine residues of protein kinase that are central to cell survival, such as 
Akt (Ser473) and the substrate thereof GSK-3 (Ser9). This evidence suggested that 
a yet-to-identify protein phosphatase, which reasonably might be thought to be 
downregulated by Lyn, was involved in the dephosphorylation of these proteins. 
Interestingly, SFK inhibitors also induced the dephosphorylation of the inhibitory 
site of the tyrosine phosphatase SHP-1, S591, raising the question whether SHP-1 
might be implicated in the control of apoptosis and hence might represent a 
potential pharmacological target (see below for details). Importantly, the fact that 
the dephosphorylation of these factors was counteracted by okadaic acid at 
concentrations within the nanomolar range led to the reasonable hypothesis that the 
protein phosphatase responsible for these events was Protein Phosphatase 2A 
(PP2A) (Zonta et al., 2015). This was also corroborated by the observation that two 
mechanisms of inhibition of the phosphatase itsef occurred, namely a) PP2A was 
phosphorylated at Tyr307 of its catalytic subunit (PP2Ac), an inhibitory site 
targeted by tyrosine kinase (Barisic et al., 2010), plausibly Lyn in CLL, considering 
its overactivity and that b) the oncoprotein SET/I2PP2A, which is known to act 
acts as PP2A endogenous inhibitor (Christensen et a., 2011), was tightly bound to 
PP2A, this interaction being strengthened by the phosphorylation at Tyr307 (Zonta 
et al., 2015).  
For a better understanding of the role of the inhibition of phosphatases in CLL, the 
structure, regulation and function of PP2A and SHP-1 illustrated below. 
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PROTEIN PHOSPHATASE 2A: MASTER REGULATOR OF VIRTUALLY 
ALL CELLULAR PROCESSES 
Protein Phosphatase 2A (PP2A) constitutes a major family of serine/threonine 
phosphatases, being ubiquitously expressed and highly conserved among the 
species (mostly eukariotes) (Sangodkar et al., 2016). It is also abundantly 
expressed, accounting for up to 1% of total cellular protein in some tissues (Shi, 
2009) and contributing, along with Protein Phosphatase 1, to over 90% of all 
serine/threonine phosphatase activities in most tissues and cells (Eichhorn et al., 
2009). PP2A regulates a great variety of cellular functions including metabolism, 
cell cycle, DNA replication, transcription and translation, proliferation, and 
apoptosis (Seshacharyulu et al., 2013). Its role as a tumor suppressor was first 
suggested when okadaic acid (OA), an already known carcinogen, was shown to 
selectively inhibit PP2A (Nagao et al., 1989). Additional evidence that its 
inhibition might lead to malignant transformaton emerged from studies on the 
oncogenic simian vacuolating virus 40 (SV40) small T-antigen, probably capable 
of disrupting the heterotrimeric structure of PP2A (Mumby, 1995). Furthermore, 
different components of the PP2A holoenzyme were shown to be mutated in 
various forms of cancer, e.g. CML, acute myeloid leukemia (AML) or lung cancer; 
on the other hand, the restoration of PP2A activity has been shown to induce cell 
death in cancer cells (both in vitro and in vivo) and counteract uncontrolled 
proliferation (Eichhorn, 2009; Oaks and Ogretmen, 2015). 
 
PP2A: structure 
Active PP2A holoenzyme is composed of three main subunits,  
 PP2AC, the catalytic subunit (in green in figure 6) 
 PP2AA, the structural subunit (in red) 
 PP2AB, the regulatory subunit (in blue). 
The core of the enzyme is made up of PP2AC and PP2AA, and can exist as a dimer 
(one third of the total cellular PP2A) or associated with one of the different types 
of B subunits. The numerous genes and isoforms of PP2A subunits result in a large 
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heterogeneity of PP2A holoenzymes (Ramaswamy  et al., 2015), with nearly 100 
possible PP2A holoenzymes that can be found in the cell (Haesen et al., 2014). 
 
PP2AC: the catalytic subunit 
PP2AC is responsible for the catalytic activity of the enzyme. PP2AC is a 36 kDa 
subunit, with two isoforms, Cα and Cβ, having 97% identity in their primary 
sequence (Seshacharyulu et al., 2013; Janssens and Goris, 2001). These two 
isoforms are ubiquitously expressed (with peaks in brain and the heart), being 
PP2ACα predominant at the plasma membrane and PP2ACβ in the cytoplasm and 
nucleus; their expression levels are different, since the α isoform is 10 times more 
abundant than β. (Janssens and Goris, 2001). As explained below, this subunit 
undergoes a variety of post-translational modifications and interacts with protein 
partners, which all affect the enzyme activity. 
 
 
PP2AA: the structural subunit 
PP2AA, also known as PR65 or structural subunit, is the structural docking platform 
for the subunits B and C. The structure of PP2AA is composed of 15 tandem repeats 
of 39 amino acids termed HEAT (huntingtin/elongation/A subunit/TOR) motif 
Figure 6. PP2A heterotrimer; modified from PDB ID: 2NYM. 
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(Janssens and Goris et al., 2001). As already seen for PP2AC, also PP2AA is 
encoded by two genes which lead to the production of two protein isoforms, α and 
β, which share around 87% of sequence identity and a molecular weight of 65 kDa. 
90% of PP2A holoenzymes contain the α isoform and 10% the β, likely due to 
different roles in the cell.  
 
PP2AB: the regulatory subunit 
PP2AB represent the most heterogeneous group of PP2A subunits, which totally 
lack structural similarities (Eichhorn et al., 2009; Janssens and Goris, 2001). The 
presence of this subunit is extremely important in that it is related to tissue 
expression, interaction with protein partners and substrate specificity. They can be 
classified into four distinct families. 
 
B family (PR55) 
This first family comprises four distinct subunits of 55 kDa each (called α, β, γ, δ,). 
α and δ are mostly ubiquitous in comparable amounts, β and γ are highly enriched 
in the brain. One of the most interesting features of this family is the presence of 
five degenerate Trp/Asp-40 (or WD-40) repeats, i.e. sequences composed of a 
partially conserved 40 amino acid sequence and ending with Trp-Asp. These 
portions are thought to mediate protein-protein interaction, for example the one 
with TGF- β receptors (Janssens and Goris, 2001). 
 
B’ family (PR61) 
These subunits have a molecular weight of 61 kDa and are encoded by five genes 
which, due to their splice variants, lead to the production of seven subunits. They 
show a peculiar and precise distribution in the cell: α, β, and ɛ are mostly found in 
the cytoplasm, γ1, γ2 and γ3 are mostly found in the nucleus, while B’δ is expressed 
in both compartments the nucleus and the cytoplasm (Eichhorn et al., 2009). All 
the PR61s are structurally similar in the central part (80% of sequence identity), 
differing at N- and C- termini. It has been shown that this type of subunits exposes 
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a highly acidic surface, which is believed to be responsible of further protein 
recruitment (Eichhorn et al., 2009).  
 
B’’ family (PR72) 
Little is known about this family, even as to the number of the members, though it 
is thought that there are four to five (Janssens and Goris, 2001). While PR130 is 
ubiquitous, PR72 is expressed exclusively in the heart and skeletal muscle, (with 
highest levels in heart and muscle), PR59 in testis, kidney, liver, brain, heart and 
lung; PR48 and G5PR are still matter of discussion (Seshacharyulu  et al., 2013; 
Janssens and Goris, 2001) 
 
 B’’’ family 
These subunits have been shown to share a conserved structure with WD-40 repeats 
that are typical for B family. They are involved in Ca2+-mediated signaling 
(Janssens and Goris, 2001).  
 
PP2A: function 
Considering the potential impressive number of combinations of its subunits, it is 
reasonable to assume that PP2A has a considerable number of functions. As a 
master regulator of signal transduction, PP2A directly influences cell proliferation, 
differentiation, adhesion, migration, metabolism and, most of all, survival (Haesen 
et al., 2014). Figure 7 shows only a few of the substrates regulated by PP2A 
(Ciccone et al., 2015).  
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PP2A as a tumor suppressor 
PP2A is considered a tumor suppressor. First evidence was the pro-oncogenic 
effect of okadaic acid (OA), a specific PP2A inhibitor (Bialojan and Takai, 1988). 
However, stronger evidence arose from studies on eukaryotic cells, which showed 
how the imbalance of the expression of one or more subunits caused severe 
misregulation in cell life; for instance,  
 overexpression of PP2AAα, which leads to the sequestration of the catalytic 
subunit, subsequent inefficient dephosphorylation and activation of myosin 
light chain kinase followed by inhibition of cytokinesis and the formation of bi- 
or multi-nucleated cells (Wera et al., 1995);  
 truncation of PR61 leads to radio-resistance and metastasis, PP2A being 
involved in the regulation of paxillin and Mdm2 (inhibitor of the p53 tumor 
suppressor). The decreased dephosphorylation of paxillin (adaptor molecule 
Figure 7. PP2A is involved in various cellular signals ranging from growth, survival to the 
cell cycle, to name a few. PP2A down-regulation may affect multiple pathways resulting in 
alteration of apoptosis, cell growth, proliferation, and differentiation in adult cells (from 
Ciccone et al., 2015). 
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involved in cell migration), enhances cell motility promoting metastasis (Ito et 
al., 2000); 
 mutations of PP2AA have been demonstrated to be present in a variety of human 
cancers, specially lung tumors, lung-derived tumors and colon tumors (Wang 
et al, 1998), while mutations of PPP2R1B gene are involved in the onset of 
almost all types of colorectal cancers (Takagi et al., 2000); 
 deletion of PR55 in eukaryotes leads the activation of MAPK signaling, 
responsible for cell overgrowth (Silverstein et al., 2002); the deletion of either 
PP2AA or PP2AC provokes the disappearance of all PP2A subunits; ablation of 
total PP2A by using dsRNA against either A or C subunit enhances ERK 
activation (Silverstein et al., 2002). 
 
This information indicates that a broad comprehension of the properties and the 
regulation of this enzyme could lead to a new approach in new strategies of 
cancer treatment. 
 
PP2A and apoptosis  
Apoptosis – or programmed cell death - is a crucial event for cellular turnover; lack 
or excessive apoptotic signals is a common hallmark of diseases such as 
neurodegenerative disorders, ischemia, autoimmune disorders and cancer. The 
capability of modulating cell life and death is an extremely desirable 
pharmaceutical aim because of its huge therapeutic potential (Elmore, 2007). 
For instance, β-catenin is a central component of the Wingless-type MMTV 
integration site (Wnt)/β-catenin pathway. β-catenin activates growth and anti-
apoptotic mechanisms due to the activation of c-MYC genes. PP2A inactivates this 
pathway and blocks these pro-survival signals (Perrotti and Neviani, 2013). 
PP2A is also involved in one of the main apoptosis-modulating signaling cascades: 
the phosphoinositide 3-kinase (PI3K)/Protein kinase B (AKT) pathway, which 
supports cell survival, proliferation, cell cycle progression, proliferation, 
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angiogenesis, and self-renewal of stem cells (Yoon et al., 2010). PP2A suppresses 
this pathway by directly dephosphorylating and inactivating Akt and by 
suppressing Akt-activation signals (Ciccone et al., 2015). Akt exerts an anti-
apoptotic effect by inhibiting the release of cytochrome C from mitochondria 
through phosphorylation of BAD (Bcl-2-associated death promoter) as well as pro-
caspase-9 (Perrotti and Neviani, 2013). The same pathway partly also involves the 
inactivation of Bcl-2 (B-cell lymphoma 2), an anti-apoptotic factor, and the 
activation of BAD and Bim (Bcl-2-like protein 11).  
 
PP2A: regulation 
Considering the fundamental function of PP2A, it must be strictly regulated. 
Moreover, given the many possible isoform combinations, the modes of regulation 
of PP2A are quite heterogeneous, and can be classified mainly into post-
translational modifications and interaction-mediated modulation. 
 
Post-translational modifications 
The main post-translational events that can affect PP2A activity are 
phosphorylation and methylation, both occurring on the catalytic subunit.  
The phosphorylation of Thr304 provides steric hindrance hampering the 
recruitment of other subunits, while that of Tyr307 prevents methylation of the C-
terminus, which occurs at Leu309 and is mediated by Leu-carboxyl 
methyltransferase of type I (LCMT1) (Perrotti and Neviani, 2013). The addition of 
a methyl residue to the Leu leads to the recruitment of B subunits other than than 
B’ and B’’, which instead prefer non-methylated PP2AC (Perrotti and Neviani, 
2008). 
 
Physiological modulators: cellular inhibitors 
I1PP2A  
The inhibitor-1 of PP2A (I1PP2A), also known as acidic leucine-rich nuclear 
phosphoprotein 32 A (ANP32A), is a 32-kDa sphingosine/dimethylsphingosine-
sensitive PP2A inhibitor (Habrukowich et al., 2010). It also functions as part of the 
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histone acetyltransferase regulatory INHAT complex in the nucleus, which also 
contain, as will be discussed below, another PP2A inhibitor, the oncoprotein named 
I2PP2A/SET) (Seo et al., 2001). It interacts with the catalytic subunit of PP2A 
(PP2AC) alone or when the latter is complexed with PP2AA. This binding is 
weakened by tyrosine phosphorylation of ANP32A, with consequent elevation of 
PP2A activity (Yu et al., 2004).  
 
I2PP2A (SET)  
The inhibitor-2 of PP2A (I2PP2A), also known as SET (Suvar3-9, enhancer of 
zeste, trithorax, hereafter referred to as SET) is a 28-kDa protein (Figure 8) that is 
able to interact and inhibit PP2AC. Its function is also regulated by the 
phosphorylation of a number of serine residues including Ser9, which interferes 
with the nuclear localization signal and accounts for its retention within the 
cytoplasm (Yu et al., 2013). The constitutive phosphorylation that results from the 
SET’s inhibitory action involves PP2A substrates including Akt, PTEN, ERK1/2, 
Mcl-1, c-Myc, c-jun, and pRb (Haesen et al, 2014), which can then dysregulate a 
number of signaling pathways giving rise to diseased conditions such as cancer 
above all (Ruvolo et al., 2016). 
 
 
Figure 6. Crystal structure of SET protein, monomer (modified from PDB ID 2E50). 
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CIP2A  
CIP2A  (cancerous  inhibitor  of  PP2A) is a 90-kDa oncoprotein which was found 
to be tightly bound to PP2AA rather than the catalytiuc subunit of the heterotrimer, 
in lymphocytes from leukemia patients. Scarcely expressed under physiological 
conditions, its overexpression is associated to the development of a great number 
of neoplasias, although a lack of expression alters spermatogenesis. Several 
oncogenic transcription factors including Ets, Myc and E2F increase the expression 
of CIP2A, which in turn represents a marker of cancer aggressiveness and poor 
prognosis (Khanna et al., 2013). CIP2A ultimately correlates with the 
phoosphorylation and stability of c-Myc, enhanced Akt-mediated signaling, and 
dysregulation of protein kinases implicated in the regulation of the cell cycle such 
as NEK2 and PLk1. In addition, the activation of the mTOR  pathway has been 
observed (Haesen et al,,  2014). 
 
Physiological modulators: cellular activators 
Ceramides 
Ceramides are sphingolipids composed of a fatty acid bound to the amine moiety 
of sphingosine (Figure 9). These are sphingolipid metabolite and structural 
components of the cell membrane with potent signaling properties (Janssens and 
Rebollo, 2012) as well as characteristic activators of PP2A. Ceramides has been 
shown to activate or restore the pro-apoptotic activity of PP2A, but the mechanism 
by which this occurs is poorly understood. It has been reasonably hypothesized that 
this sphingolipid binds to SET, thereby interfering with the formation of a 
SET/PP2A complex and preventing the inhibition of the phosphatase activity 
(Saddoughi et al., 2013). In this regard, ceramide can induce apoptosis in prostate-
Figure 9. Ceramide 
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cancer cells by suppressing the Akt signaling pathway, which depends on the 
reactivation of PP2A (Perrotti and Neviani, 2013). As will be discussed later, an 
analogue of spingosine, the ceramide precursor, named fingolimod (FTY720, 
Gilenya®, Figure 6), a drug approved for oral therapy in multiple sclerosis, has 
proved effective in activating PP2A by interfering with the interaction with SET 
(Saddoughi et  al., 2013).  
 
Non-physiological inhibitors 
Okadaic acid (OA) 
OA is the prototypical PP2A inhibitor, a toxin produced by dinoflagellates 
(Reguera et al., 2014), and that reversibly binds within the catalytic pocket of 
PP2AC. At concentrations within the nanomolar range, it proves highly selective 
towards PP2A, which has allowed for the exploration of PP2A as a tumor 
suppressor.  
 
Forskolin 
Forskolin is a diterpene capable of raising the intracellular levels of cAMP, but also 
to activate PP2A, especially in the form of 1,9-dideossi  forskolin, which lacks the 
ability to activate adenylyl cyclase. In CML, a marked apoptosis has been observed 
following reactivation of PP2A by forskolin (Perrotti e Neviani,  2013).  
Figure 10. Okadaic acid 
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Fingolimod (FTY720)  
As mentioned above, fingolimod (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-
1,3-diol, hereafter FTY720, Figure 12) is the first oral drug approved in the 
treatment of the relapsing-remitting form of multiple sclerosis and marketed as 
Gilenya® by Novartis. First identified within a library of compounds synthesized 
in an effort to develop derivatives of myriocin, a metabolite of the fungus Isaria 
sinclairii sharing close structural similarity to sphingosine and displaying a potent 
immunosuppressive action by inhibiting serine palmitoyltransferase, a crucial 
enzyme in sphingolipid metabolism (Miyake et al., 1995), FTY720 sparked 
considerable interest in the area of organ transplantation in that a number of 
preclinical studies using animal models demonstrated the efficacy of FTY720, 
alone or in combination with cyclosporine, in prolonging solid organ allograft 
survival. (Brinkmann and Lynch, 2002; Budde et al, 2006). Importantly, FTY720 
is considered a prodrug, because it must first be phosphorylated by sphingosine 
kinase 2 (SK-2) (Pelletier and Hafler, 2012; Pitman et al., 2012; Cyster and 
Schwab, 2012), to be pharmacologically active (Figure 13). As a result, it mimics 
Figure 11. Forkolin 
Figure 12. Chemical structure of fingolimod (FTY720) 
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the action of sphingosine-1-phosphate (S1P) by interacting with the class of G 
protein-coupled receptors named S1P receptors (S1P1 and S1P3-5, but not S1P2), 
S1P1 in particular, which is highly expressed on the plasma membrane of activated 
T lymphocytes (Figure 14).  
In contrast with S1P, which modulates the diverse functions of a variety of cells 
through differential coupling of the receptor to heterotrimeric G-proteins (αI, αq or 
α12/13) and through heterogeneity in terms of the constitutive and inducible patterns 
Figure 13. Phosphorylated form of fingolimod (FTY720)  
Figure 14. The phosphorylated form of fingolimod (FTY720) is extruded from the cell, 
thereafter binding to, and bringing about the internalization of S1P receptors, S1P1 in 
particular (from Brinkmann et al., 2010). 
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of expression of the S1P receptors themselves in.immune cells (Rivera et al., 2008), 
FTY720 strongly binds to S1P1 provoking its internalization and degradation rather 
than thereby preventing egression of T lymphocytes from lymphoid organs, which 
is the basis for the immunosuppression (Lee et al., 2010). Importantly, its ability to 
activate PP2A depends on its non-phosphorylated form, as demonstrated by the 
silencing of SK-2 (Saddoughi et al., 2013), which confers antitumor activity to 
FTY720, especially against hematologic malignancies (Oaks et al., 2013). The 
structure of FTY720 has recently been used as a template to design new molecules 
devoid of immunosuppressive action (Zonta et al., 2015), a characteristic highly 
desirable for the development of compounds that might be considered for pre-
clinical studies or hopefully clinical trials including patients afflicted by any type 
of cancer. In our laboratories, new FTY720 analogues have recently been 
synthesized  with a structure that retains specific features for the interaction with 
SET (Zonta et al., 2015). The preliminary successful tests have led to the 
development of a library of compounds that are now included in a patent 
application recently filed at the national patent office.  
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SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE 1 (SHP-1)  
Tyrosine phosphorylation, whether occurring upon engagement of Receptor 
Tyrosine Kinases (RTK) or being mediated as a result of the involvement of Non-
Receptor Tyrosine Kinases (NRTK), is a critical event that initiates and regulates 
a myriad of cellular processes including growth factor receptor signaling, cell 
adhesion, metabolism, cell cycle control, transcriptional activation, to mention but 
a few (Hunter, 2009). This flow of information, which occurs through the 
integration of the great variety of signaling pathways being activated 
simultaneously, can be interrupted by the other actors of reversible tyrosine 
phosphorylation, namely protein tyrosine phosphatases (PTPs). As in the case of 
serine/threonine phosphatases, accumulating evidence shows that these are not 
merely the off-switches of signaling pathways, but contribute to the fine tuning of 
intracellular communication, so that the diverse stimuli yield generate specific 
effects that meet the cellular needs any time (Ostman and Böhmer, 2001). This 
multifaceted function can be well exemplified by the action of two members of the 
Src Homology 2 domain-containing Phosphatase (SHP) family 1 and 2, SHP-1 and 
SHP-2 for short (Neel et al., 2003; Chong and Maiese, 2007), which, though 
sharing high sequence homology, often play opposite biologic roles. As to their 
expression, SHP-1  is  mainly present in hematopoietic and epithelial cells and is 
widely regarded as a negative regulator of signaling, whereas SHP-2 is  ubiquitous 
and shown to have a role in promoting cell activation (Neef et al., 2006; Shaker et 
al., 2011; Thabut et al., 2011; Forbes et al., 2012). As to their role in disease, 
especially in cancer development, the absence of SHP-1 expression has been 
observed in several forms of lymphomas and leukemias (Ma et al., 2003; Neel, 
1993; Wu et al.,2003), which underlines the role of SHP-1 as a tumor suppressor, 
whereas the uncontrolled activation of SHP-2 is considered an oncogenic factor 
(Irandoust et al., 2009).This chapter will focus on SHP-1, which is known as a 
negative regulator of signaling pathways downstream of several RTKs and now 
deemed a potential target for cancer therapy (Watson et al., 2016; López-Ruiz et 
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al., 2011). In CLL cells in particular, it has been recently demonstrated that SHP-1 
is segregated into two forms, one in an active form being bound to the inhibitory 
co-receptor CD5, and the other in the cytosol in an inhibited conformation due to 
its phosphorylation of an inhibitory residue, both contributing to the resistance to 
apoptosis (Tibaldi et al.,  2011).  
SHP-1: structure 
SHP-1 is encoded by the PTPN6 gene, the splicing of which gives rise to four 4 
gene products, 3 variants of SHP-1 with different N-termini and a long form of 
SHP-1 termed SHP-1L where the C-terminus is extended. As shown in Figure 15A, 
the SH2 domains are situated at the N-terminus of the molecule, followed by the 
catalytic domain and a C-terminal tail. This latter is displayed in more detail in 
Figure 15B, where critical residues for the regulation of the catalytic activity are 
emphasized. In the inactive conformation, the N-terminal SH2 domain is 
intramolecularly associated with the PTP domain, thereby repressing its activity, 
A 
B 
Figure 15. (A) Structural characteristics of SHP-1 variants (from Poole and Jones, 2005). (B) 
Structure of SHP-1 and sequence of the C-terminus with tyrosyl (Y, Tyr536 and Tyr564) and seryl 
(S, Ser591) residues playing a crucial role in the activation and inhibition of the phosphatase 
respectively. 
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whereas the engagement of the SH2 domains leads to the activation of the 
phosphatase. Figure 16 shows that, whether due to the binding of the SH2 domains 
to the phosphorylated tyrosyl residues of Immunoreceptor Tyrosine Inhibitory 
Motifs (ITIMs, Figure 16A) in inhibitory cell surface co-receptors such as CD22 
(Cyster and Goodnow, 1997), CD72 (Adachi et al., 1998), and CD5 (Tibaldi et al., 
2011), or to the intramolecular interaction with the phosphorylated form of Tyr536 
and Tyr 564 in the C-terminus (Figure 16B) (Zhang et al., 2003), the inhibition of 
SHP-1 is relieved. Besides the interaction of the N-terminal SH2 domain with the 
PTP domain, another mechanism of inhibition of SHP-1 is the phosphorylation of 
Ser591 by PKC or MAPK, which has not been described for SHP-2 (Jones et al., 
2004; Poole and Jones, 2005).  
 
SHP-1: function 
Basically, SHP-1 is a regulator of haematopoietic cells, downregulating the 
pathways that promote cell growth and survival (Zhang et al., 2000), among others. 
In other types of cells, it also attenuates and terminates signals involved in cell 
proliferation, differentiation, survival, and apoptosis (Duchesne et al., 2003; Wu et 
al., 2003; Valencia et al., 1997; Keilhack et al., 2001; Tenev et al., 2000). SHP-1  
also  regulates glucose  homeostasis  by modulating insulin signaling  in  liver  and  
Figure 16. Models of the activation of SHP-1 based upon the engagement of the SH2 domains 
with phosphorylated tyrosyl residues of receptors or protein partners (A) or harbored within the 
C-terminus of the phosphatase. (from Poole and Jones, 2005). 
 43 
 
muscle (Dubois et al., 2006) and negatively affects bone resorption (Aoki et al., 
1999).  
SHP-1 performs these functions by either directly dephosphorylating the the 
cytosolic tails of the RTKs that become activated upon engagement with their 
respective ligands including Platelet-Derived Growth Factor Receptor (PDGFR), 
Insulin Receptor (IR), the Epidermal Growth Factor Receptor  (EGFR), and 
Vascular Endothelial Growth Factor Receptor (VEGFR) type 2 (Geraldes et al., 
2009; Dubois et al., 2006; Tenev et al., 1997; Bhattacharya et al., 2008), or 
components of the immune receptors that do not possess kinase activity such as 
from the activation of a variety of plasma membrane receptors including the B Cell 
Receptor (BCR) (Adachi et al., 2001), T Cell Receptor (TCR) (Perez-Villar et al., 
1999), and NK Activating Receptor (Matalon et al., 2016). As previously 
mentioned and exemplified in Figure 17, this latter function occurs especially when 
SHP-1 is recruited to the ITIMs of the inhibitory receptors, such as CD5, CD22, 
CD72, FcγRIIB, p70-NKB1 and KIR. (Zhang et al., 2000; Silver and Cornall, 
1. Figure 17. Role of SHP-1 in downregulating signals from plasma membrane receptors. The 
phosphorylation of the of inhibitory ITIMs of inhibitory receptors results in the recruitment of the 
cytosolic phosphatase SHP-1 with dephosphorylation of cytosolic tails of the plasma membrane 
receptors initiating signal transduction. Here, the action of SHP-1 on the signals downstream of BCR 
engagement is shown. Importantly Lyn is unique among the tyrosine kinases in immune cells, in that 
it takes part in negative feedback (from Silver and  Cornall, 2003) 
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2003), once these are uniquely phosphorylated by the SFK Lyn (Tibaldi et al., 
2011). Moreover, SHP-1 downregulates signals mediated by non-receptor tyrosine 
kinases (especially those belonging to the Src family) and downstream mediators 
that participate in signal transduction such as Erk,  JNK  STATs, Jak2,  NF-kB,  
and  PI3K-Akt  (Chong and Maiese, 2007).   
The  current  understanding  of  the highly  complex  function  of SHP-1 has posed 
the question whether it might represent a new attracting target for drug 
development, especially in diseases where its activity is suppressed, as in the case 
of several types of cancer (Sharma et al., 2016; Watson et al., 2016). Importantly, 
drugs already used in the clinical practice as multi-kinase inhibitors have recently 
proved to be direct activators of SHP-1, the molecular models showing that these 
compounds may intervene in the inhibitory mechanism mediated by the N-terminal 
SH2 domain (Tai et al., 2014a). In the following sections, more details will be 
provided as to their interaction with SHP-1 and their potential role as templates for 
the development of more selective compounds to be employed in cancer therapy. 
 
SHP-1 activators: angiokinase inhibitors doing a front flip? 
In the past few years, drugs already approved as multi-angiokinase inhibitors 
directed against RTKs such as PDGFR and VEGFR in particular, have emerged as 
agents capable of activating SHP-1, including sorafenib (Figure 18A) (Wilhelm et 
al., 2008) and nintedanib, also known as BIBF-1120 (Figure 18B) (Tai et al., 
2014a). Many derivatives of the former have been developed and tested in a number 
of cancer models, including hepatocellular carcinoma (Tai et al, 2014b) and triple 
negative breast cancer cells (Liu et al., 20117), exploiting this phosphatase-directed 
potential. As to nintedanib, it has been approved for the treatment of pulmonary 
fibrosis and second-line therapy of lung adenocarcinoma (McCormack, 2015) and 
now being evaluated in further clinical trials. Interestingly, a docking model has 
been proposed for nintedanib targeting SHP-1, based upon the interaction with 
Glu524 through hydrogen bonding (Tai et al., 2014a), residue that lies in the close 
proximity to the catalytic domain of the phosphatase and may account for a steric 
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hindrance preventing the inhibited conformation promoted by the N-terminal SH2 
domain. In our leukemia model, we also had observed that the phospho-Ser591-
dependent inhibition occurred, which , according to other authors (Tai et al., 2014a) 
can be circumvented by nintedanib itself, which operates independently of post-
translational regulatory mechanisms, possibly driving conformational changes with 
subsequent activation of the phosphatase. In Figure 19, the docking model 
describing the SHP-1/nintedanib interaction is shown. 
 
A 
B 
Figura 18. Sorafenib (A) and nintedanib (B) 
Figura 19. Model of interaction between nintedanib and SHP-1 
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Notably, these studies show that a crucial target for SHP-1 is the phosphorylated 
form of the family of Signal Transducer and Activator of Transcription (STAT) 
proteins, and STAT3 in particular, whose activity as cytoplasmic signaling protein 
and nuclear transcription factor is frequently elevated in a variety of solid tumors 
and hematological malignancies and which is abolished by the treatment with 
sorafenib, nintedanib or derivatives thereof (Yang et al., 2008; Abdulghani et ., 
2013; Su et al., 2016; Chen et al., 2012; Tai et al., 2014a).  
 
 
. 
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RATIONALE OF THE STUDY 
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This study draws upon previous observations concerning the functional status of 
critical enzymes in the signal transduction of CLL cells, which directly depends on 
the phosphorylation of specific factors at regulatory residues and in specific 
compartments as well as the interaction with protein partners that affect their 
activity. More in detail, having assessed that the inhibitory seryl residue of SHP-1 
is dephosphorylated by PP2A (Zonta et al., 2015), the aim of this work was  
 
 to assess whether he restoration of PP2A activity by the FTY720 analogue 
MP07-66 might lead to SHP-1 activation, resulting in the suppression of the 
Lyn-dependent pervasive tyrosine phosphorylation that characterizes CLL 
cells and is shown to be an anti-apoptotic factor;  
 to attempt to activate SHP-1 directly by using nintedanib, which in addition 
to acting as a triple angiokinase inhibitor, is capable of circumventing the 
phospho-S591-dependent inhibition of the phosphatase;  
 to establish whether the activation of SHP-1 affected the level of 
phosphorylation of PP2AC at Tyr307, a residue that was shown to be crucial 
for a tight interaction of PP2A with SET and the total inhibition of the 
phosphatase activity of PP2A itself, and this effect might ignite a virtuous 
cycle that could potentiate the action of both of these tumor suppressors. 
 
In addition to providing further insight into the molecular basis of CLL, the results 
achieved in this study might put forward new prospects in the development of 
alternative strategies in the treatment of CLL by mobilizing endogenous resources 
(phosphatases), which are typically inhibited in cancer cells rather than suppressing 
active players (e. g. kinases), which may be operating in normal tissues  at the same 
time, with consequent adverse undesidered effects. 
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EXPERIMENTAL SECTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 50 
 
 
Nintedanib directly activates SHP-1 in the cytosol of CLL cells 
We previously demonstrated that SHP-1 is present in CLL cells in two forms, one 
bound to the plasma membrane receptor CD5 in an active state, and the other in the 
cytosol in an inhibited conformation (Tibaldi et al., 2011). As shown in Figure 20A, 
the plasma membrane-enriched fraction (particulate) and the cytosol of CLL cells 
were separated from total lysates and immunoblotted with anti-pY536-SHP-1 and 
anti-pS591-SHP-1 antibodies, a positive response to which is indicative of either 
activation or inhibition of SHP-1, respectively. As expected, the distribution of 
SHP-1 in the two cellular compartments paralleled the functional status, these 
characteristics turning out to be independent of the diverse biological and clinical 
features of the single patients (Table 2). Moreover, in order to establish how the 
phosphorylation status affected SHP-1 activity, SHP-1 was pulled down from the 
cytosolic and particulate fractions and tested for the phosphatase activity by using 
32P-labeled Band 3 as a substrate (Tibaldi et al., 2014). The phosphatase activity of 
SHP-1 exhibited by the cytosolic fraction was negligible as compared to that of the 
particulate (Figure 20B), underscoring that the catalytic activity of SHP-1 can be 
profoundly affected by the phosphorylation at different residues. This finding 
raised the question whether the inhibition of the pool of SHP-1 in the cytosol was 
related to the elevated level of tyrosine phosphorylation CLL cells in this 
compartment, which was previously shown to characterize this disease and to 
promote anti-apoptotic mechanisms (Zonta et al., 2015). Therefore, we first 
performed in-vitro phosphatase activity assays on the cytosolic pool of SHP-1 in 
the presence of nintedanib (Figure 20), which in addition to acting as receptor 
tyrosine kinase inhibitor (Hilberg et al., 2008), (Roth et al., 2009) has been shown 
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to remove the pS591-dependent inhibition of SHP-1 (Tai et al., 2014). To this end, 
SHP-1 was pulled down from the cytosolic fraction of CLL cells in the absence or 
the presence of serine/threonine phosphatase inhibitors in order to assess the effect 
of increasing concentrations nintedanib on the activity of the phosphorylated and 
2 
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non-phosphorylated forms of SHP-1 (Figure 20C, inset). Figure 20C shows that 
Figure 20. In-vitro effect of nintedanib on the differently phosphorylated forms of SHP-1 pulled down from CLL cells. 
(A) Whole cell lysates, particulate and cytosol of 5 x 105 CLL cells underwent Western blot (Wb) analysis with anti-pS591-
SHP-1 and pY536-SHP-1 antibodies and reprobed with anti-SHP-1, anti-LDH (cytosolic marker) and anti-PMCA (plasma 
membrane marker) antibodies as loading  controls. #2, #17, #22, #24, #34 and #35 are patients belonging to various clinical 
and biological subtypes. (B) Tyrosine phosphatase activity of SHP-1 immunoprecipitates recovered from particulate and 
cytosol of CLL cells. (C) Tyrosine phosphatase activity of SHP-1 immunoprecipitated from the cytosol of CLL cells of 15 
patients in the absence (Ip1-SHP-1) and presence (Ip2-SHP-1 1) of serine/threonine phosphatase inhibitors and determined in 
vitro in the presence of increasing concentrations of nintedanib supplemented without (solid circles) or with 25 µM PTP I-I 
(open circles). The inset shows the level of pS591-SHP-1 determined by Wb analysis and reprobed, after stripping, with anti-
SHP-1 antibody as loading control pertaining to from the patient #34 (left-hand panel) and the pooled densitometric analysis 
(arbitrary units, right-hand panel) of the patients examined. The data are the mean ± SD of 3 experiments performed in triplicate 
(*P ≤ 0.01).  
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nintedanib was capable of activating the phosphorylated, and inhibited, form of 
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SHP-1 (Ip2-SHP-1, right-hand panel), as expected on the basis of previous data  
Figure 21. Effect of nintedanib on the activity of the differently phosphorylated forms of SHP-1 inside CLL cells (A) 
The activity of SHP-1 immunoprecipitated from cytosol (left-hand panel) and particulate (right-hand panel) of freshly 
isolated CLL cells cultured in the absence or presence of increasing concentrations of nintedanib for 1 h was measured as 
[32P]phosphate released from [32P]phospho-band 3. (B) Wb analysis of cytosol and particulate from freshly isolated CLL 
cells were cultured in the presence of 15 µM nintedanib over time performed with pS591-SHP-1 and pY536-SHP-1 
antibodies. (C) SHP-1 immunoprecipitated from the cytosol (left-hand panel) or particulate  (right-hand panel) of the CLL 
cells described in (B), was tested for the basal tyrosine phosphatase activity in vitro on [32P]phospho-band 3. (D) 
Densitometric analysis of Western blots probed with anti-pS591 or alternatively anti-pY536 antibody of all the 16 patients 
(arbitrary units, open circles, left- and right-hand panel respectively) as well as the values of the phosphatase activity reported 
as histograms in (C), normalized as percentage (solid circles, left- and right-hand panel respectively). The data are the mean 
± SD of 3 experiments performed in triplicate (*P ≤ 0.01). 
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(Tai et al., 2014), whereas the non-phosphorylated form was not influenced by the 
compound in that  the phosphatase was already active (Ip1-SHP-1, left-hand panel). 
These results appear to be in line with the hypothesis that this drug causes a change 
in the inhibited conformation of SHP-1 induced by the phosphorylation at S591. 
Similarly, we analyzed the activity of SHP-1 immunoprecipitated from the 
cytosolic and particulate fractions of CLL cells treated with increasing 
concentrations of nintedanib, considering that SHP-1 in these compartments is 
differently phosphorylated and active. As shown in Figure 21A, SHP-1 reached a 
full activation at a concentration as high as 15 µM nintedanib  (left panel), as 
determined by measuring the dephosphorylation of 32P-band 3, whereas the one 
from the particulate was unaffected (right panel). After incubating CLL cells over 
time at 15 µM nintedanib, we evaluated the phosphorylation status of SHP-1 on the 
cytosolic and particulate fractions by Western blot analysis with anti-pS591-SHP-
1 and anti-pY536-SHP-1 antibodies, respectively, and performed phosphatase 
activity assays on SHP-1 after immunoprecipitation at each time interval. 
Nintedanib affected neither the phosphorylation status (Figure 21B, right-hand 
panel), nor the catalytic activity (Figure 21C, right-hand panel) of the SHP -1 pool 
of the particulate, whereas the one in the cytosol was readily activated by 
nintedanib, reaching the maximal efficacy already at the earliest incubation times 
by circumventing the inhibitory phosphorylation at S591 (Figures 21B and 21C, 
left-hand panel). The data obtained by Western blot analysis and phosphor imaging 
were quantitated as arbitrary units and sketched in Figure 2D for clarity’s sake. 
 
Nintedanib induces activation of caspase-8 and PP2A by decreasing tyrosine 
phosphorylation in CLL cells 
We previously showed that the cytosol of CLL cells is characterized by the elevated 
level of tyrosine phosphorylation promoted by the aberrant constitutive activity of 
HSP90-bound Lyn, promoting anti-apoptotic mechanisms (Trentin et al., 2008). To 
verify whether the cytosolic tyrosine phosphorylation in CLL cells was related to 
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the inhibition of SHP-1 in this compartment, SHP-1 was silenced in freshly isolated 
leukemic B cells, which were subsequently incubated for 1 hour in the presence of 
increasing concentrations of nintedanib (0-30 μM), lysed and analyzed by Western 
blot analysis with anti-phosphotyrosine antibody. Nintedanib caused a dramatic 
reduction in tyrosine phosphorylation at a concentration of 10 µM (Figure 22A and 
22B, left panels), which was significantly high er than the nanomolar range 
reported to inhibit the receptor tyrosine kinases (RTKs) that nintedanib is known 
to target  (Hilberg et al., 2008;), (Roth et al., 2009). Importantly, its effect was 
Figure 22. Effect of nintedanib on the tyrosine phosphorylation of CLL cells. Freshly isolated CLL cells were transfected 
with either scramble RNA or SHP-1-siRNAs and incubated for 48 h in complete medium and the expression of SHP-1 was 
determined by Wb analysis (pooled densitometric analysis of all the samples tested are histogrammed in the top panel of the 
insets). The immunoblots of two samples from patients #18 (A) and #35 (B) are shown in the bottom panel in the insets. CLL 
cells were subsequently cultured in the absence or presence of increasing concentrations of nintedanib for 1 hour and whole 
cell lysates were analyzed by Wb analysis with anti-pY antibody. The Wb strips show the results concerning the patients #18 
and #35 and are representative of all the patients examined. (C, D) The global tyrosine kinase activity and the specific Src 
activity in the CLL cells cultured as in (A) and (B) was determined by using the nonspecific random polymer polyGlu4Tyr (top 
panel) or the specific peptide substrate cdc2(6-20) (bottom panel) and the pooled data are reported as histograms. The data are 
expressed as mean ± SD of 3 experiments performed in triplicate (*P ≤ 0.05).  
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abrogated by the genetic inhibition of the phosphatase itself (Figure 22A and 22B, 
right panels), and proved independent, if not to a very limited extent, to the 
inhibition of tyrosine kinases as assessed by tyrosine kinase activity assays using 
poly-Glu-Tyr or cdc2[6-20], peptide substrates used to determine the global 
(including that of RTKs) or the SFK specific activity, respectively (Gringeri et al., 
2009), (Tibaldi et al., 2011a). In fact, as histogrammed in Figure 22C and 22D, both 
types of activities were affected at most by 30% of the control only at high 
concentrations of nintedanib (over 10 µM). The hypothesis that the effect observed 
was mediated by the activation of SHP-1, rather than the inhibition of a tyrosine 
kinase, was further supported by in vitro kinase assays showing an IC50 of 12 µM 
nintedanib for Lyn at 20 µM ATP, whereas dasatinib, a SFK inhibitor, exhibited 
an IC50 of 50 nM  (data not shown). Additionally, we wanted to evaluate whether 
nintedanib could impinge upon CLL cell viability, considering that the apoptosis 
of CLL cells was already found to be related to the drug-induced decrease in 
tyrosine phosphorylation  (Contri al., 2005; Trentin et al., 2008). Therefore, fresh 
B cells isolated from CLL patients were incubated with increasing concentrations 
of nintedanib for 24 and 48 h and then subject to annexin V-PI flow cytometry. As 
shown in Figure 23A, the level of apoptosis reached 50% and 60%, at 24 hours and 
48 hours, respectively, at a nintedanib concentration as high as 10 µM (left-hand 
panel), with concomitant cleavage of PARP and caspase-3, markers of caspase-
dependent apoptosis (right-hand panel). Similar results were obtained by co-
culturing CLL cells with bone marrow mesenchymal stromal cells (data not shown) 
so as to mimic the tissue microenviroment where CLL cells proliferate (Ding et al., 
2010). 
To further investigate the contribution of SHP-1 to the nintedanib-induced 
apoptosis, we used genetic and pharmacological inhibition of the phosphatase 
itself. Figure 23B (left-hand panel) shows that the number  of apoptotic cells after 
24 hours’ treatment with nintedanib (bar 4) was dramatically reduced by the 
silencing of SHP-1 (bar 8) to levels comparable to those reached by knocking down 
the phosphatase in the absence of nintedanib (bar 6). At the molecular level, 
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nintedanib induced casp ase-dependent apoptosis, as witnessed by the cleavage of 
Figure 23. Effect of nintedanib on the viability of CLL cells. CLL cells underwent annexin V–PI flow cytometry after all 
the treatments and quadrant analysis after flow cytometry was histogrammed and expressed as mean percentage of early and 
late apoptosis ± SD from three separate experiments performed in triplicate. 5 x 105 CLL cells fro each experiment were 
lysed and analyzed by Wb analysis with anti-caspase 3 and anti-PARP antibodies to monitor caspase-dependent apoptosis, 
and anti-β-actin antibody as a loading control (right panels). (A) Apoptosis of freshly isolated CLL cells cultured in the 
absence or presence of increasing concentrations of nintedanib for 24 and 48h. Compared with the control, changes were 
statistically significant (left panel, *P ≤ 0.01). (B) After transfection of CLL cells with either scramble RNA (white bars) or 
SHP-1-siRNAs (grey bars) for 48 h in complete medium, the expression of SHP-1 was determined by Wb analysis The data 
are the mean ± SD of 3 experiments performed in duplicate. *P ≤ 0.01. CLL cells were subsequently incubated for 0 or 24 h 
in the absence (bars 1-4) or presence (bars 5-8) of 15 µM nintedanib. Compared with the control, changes were statistically 
significant (left panel, *P ≤ 0.01). (C) Freshly isolated CLL cells were incubated for 0 or 24 h in complete medium in the 
absence (bars 1-4) or presence (bars 5-8) of 25 µM PTP-I-I and supplemented without (bars 1-2 and 5-6) or with (3-4 and 7-
8) 15 µM nintedanib.  
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caspase-3 and PARP (Figure 23B, right-hand panel, lane 4), the latter event being 
negligible when silencing SHP-1, irrespective of the presence of nintedanib (lanes 
6 and 8). These findings were consistent with our previous data demonstrating that 
SHP-1 knock-down brings about caspase-independent apoptosis by targeting the 
plasma membrane pool of the phosphatase, which is catalytically active and 
orchestrates anti-apoptotic signals (Tsui et al., 2006; Tibaldi et al., 2011). The 
Figure 24: Effect of nintedanib on the 
phosphorylation state and activity of 
procaspase 8 and PP2Ac. Freshly isolated 
CLL cells were transfected with either 
scramble RNA (left-hand panels) or SHP-1-
siRNAs (right-hand panels), cultured for 48 
h in complete medium and subsequently 
cultured in the absence or presence of 
increasing concentrations of nintedanib for 
1h.  (A) After the 6 hours’ treatment 
described above, cells were lysed and 
underwent Wb analysis with anti-pY380-
procasp8 antibody. The blots were then 
stripped and reprobed with anti-procasp8 
antibody and with anti-β-actin antibody as a 
loading control. Densitometric analysis 
(arbitrary units) of the pY380-procasp8 and 
pro-casp8 bands are reported as histograms. 
Data are expressed as mean ± SD from 4 
experiments performed in triplicate. (B) 
After the 6 hours’ treatment described 
above, cell lysates were assayed for in vitro 
casp8. Compared with the effect of 
nintedanib, changes due to PTP I-I were 
statistically significant (*P ≤ 0.01). (C) 
After the 1 hours’ treatment described 
above, cells were lysed and analyzed by Wb 
analysis with anti-pY307-PP2Ac antibody. 
The blots were then stripped and reprobed 
with anti-PP2Ac antibody and with anti-β-
actin antibodies as a loading control.  
  Densitometric analysis (arbitrary units) of the pY307-PP2Ac and anti-PP2Ac bands are histogrammed. Data  are expressed as  
mean ± SD from 4 experiments performed in triplicate. (D) After the 6 hours’ treatment    described    above,   cell   lysates  
wereassayed for in vitro PP2A activity by using a specific phosphopeptide as a substrate. Compared with the effect of 
nintedanib, changes due to PTP I-I were statistically significant (*P ≤ 0.01). The data in the figure show the results concerning 
the patient #31 and are representative of all the patients examined. 
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pharmacological inhibition of SHP-1, achieved by the use of PTP-I-I, provided 
results overlapping those obtained by using SHP-1 siRNAs (Figure 22C). These 
observations led us to hypothesize that the dephosphorylation of specific SHP-1 
substrates underlay the induction of apoptosis following treatment with nintedanib 
in CLL cells. Therefore, we focused our attention on two factors that we had 
previously explored and the activity of which we found to be inhibited in CLL via 
phosphorylation by the aberrant cytosolic form of Lyn, namely the caspase-8 
zymogen (procaspase-8) (Zonta et al., 2014) and the serine/threonine Protein 
Phosphatase 2A (PP2A) (Zonta et al., 2015). After incubating freshly isolated CLL 
cells with increasing concentrations of nintedanib, we performed Western blot 
analysis with antibodies directed against the phosphorylated form of specific 
inhibitory residues of these two proteins, Y380 of procaspase-8 and Y307 of the 
catalytic subunit of PP2A (PP2Ac), respectively. Both tyrosines were 
phosphorylated when SHP-1 was not silenced nintedanib was not added, (Figure 
24A and 24C, left-hand panels, 0 μM), the level of phosphorylation gradually 
declining as nintedanib concentration increased (1-20 μM). Moreover, total lysates 
from the same samples were assayed for the activity of the two enzymes in vitro 
by using commercial kits (see Materials and Methods for details), which allowed 
us to conclude that the dephosphorylation induced by nintedanib paralleled the 
level of activation of both  enzymes (Figure 24B and 24D, left-hand panels). 
Importantly, dephosphorylation and activation were blocked, albeit in the presence 
of nintedanib, by subjecting CLL cells to SHP-1 knock-down, (Figure 24, right-
hand panels), indicating that procaspase-8 and PP2Ac are substrates for SHP-1 and 
effectors of a SHP-1- dependent pro-apoptotic pathway.  
 
Apoptosis of the CLL cells can be induced by indirect activators of SHP-1 
The data collected thus far confirmed that nintedanib could trigger SHP-1 by 
circumventing the phosphorylation at the inhibitory residue S591. Interestingly, we 
recently demonstrated that pS591 could be dephosphorylated by PP2A, the activity 
of which was impaired by the phosphorylation at Y307 as well as the interaction 
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with its endogenous inhibitor SET and restored by a fingolimod analogue devoid 
of immunosuppressive action, the so-called MP07-66 (2,2-diethoxyethyl{[4-
(hexyloxy)phenyl]methyl})amine) (Zonta et al., 2015). This latter event was shown 
to underlie the activation of apoptotic cascades based on the dephosphorylation of 
PP2A substrates (Zonta et al., 2015). These findings led us to conjecture that 
MP07-66 could be used as an indirect activator of SHP-1 via PP2A, and exploited 
to potentiate the action of nintedanib on SHP-1 itself in order to reinforce the 
apoptotic response of CLL cells. As shown in Figure 25A (left-hand panel), 
incubation with increasing concentrations of MP07-66 (0-15 µM) brought about 
apoptosis in 50% and 80% of CLL cells, at 24 hours and 48 hours, respectively, as 
determined by annexin V–PI flow cytometry. Of note, a time-course analysis of the 
cleavage of PARP indicated that apoptosis was dependent on caspase activation 
(right-hand panel). To evaluate whether SHP-1 was implicated in these events, 
aliquots from the cytosol for each time interval were immunoblotted with anti-
pS591 SHP-1 antibody and tested for phosphatase activity in the presence of 32P-
labeled Band 3, showing that the dephosphorylation of SHP-1 was concomitant 
with the elevation of the activity thereof as the concentration of MP07-66 increased 
(Figure 25B and 25C). Further evidence for the role of SHP-1 in mediating 
apoptosis of CLL cells upon treatment with MP07-66 was provided by Western 
blot analysis with antibodies against pY380-procaspase8 and pY307-PP2Ac, 
revealing the dephosphorylation of the inhibitory residues (Figure 25D, lane 6) at 
6 h. As expected, this event was blocked by the specific SHP-1 inhibitor PTP-I-I 
(Figure 25D, lane 8) as well as by okadaic acid (lane 7), which confirmed that the 
activation of PP2A drives the dephosphorylation of SHP-1 S591, in turn promoting 
global tyrosine dephosphorylation and cell demise. This latter observation is 
consistent with the hypothesis that SHP-1 and PP2A form a signalling axis wherein 
the single phosphatases, when stimulated, can activate one another, and even more 
so that such process can be amplified by using a combination of molecules 
activating both at the same time. 
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MP07-66 potentiates the pro-apoptotic effect of nintedanib 
Since our data suggest that the activation of either PP2A or SHP-1 triggered by 
specific small molecules results in stimulating each other’s activity and igniting a 
positive feed-back signalling loop that promotes apoptosis, we wondered whether 
the combination of nintedanib and MP07-66 could result in a more robust apoptotic 
response of CLL cells. Therefore, freshly isolated CLL were incubated with 15 µM 
nintedanib and 8 µM MP07-66 at different  times  and  apoptosis  was  monitored 
 
 
 
 
 
 
Figure 25: Effect of MP 07-
66 on the CLL cell survival. 
(A) Freshly isolated CLL cells 
were cultured in the absence 
or presence of increasing 
concentrations of MP07-66 
for 24 h and 48 h. After such 
treatment, cell apoptosis was 
analyzed by annexin V–PI 
flow cytometry. Quadrant 
analysis after flow cytometry 
was histogrammed and 
expressed as mean percentage 
of early and late apoptosis ± 
SD from three separate 
experiments performed in 
triplicate. Compared with the 
control, changes due to 
MP07-66 were statistically 
significant (*P ≤ 0.01). 5 x 105 
CLL cells were lysed and 
analyzed by Wb analysis with 
anti-caspase 3 and anti-PARP 
antibodies to monitor caspase-
dependent apoptosis, and anti-
β-actin antibody as a loading 
control (right panels). (B) 
Freshly isolated CLL cells 
were cultured as described in  
(A) and, cell lysates underwent Wb analysis with pS591-SHP-1 antibody. The blots were then stripped and reprobed with anti-
SHP-1 antibody. (C) Freshly isolated CLL cells were cultured as described in (A). After such treatment, SHP-1 was 
immunoprecipitated from the cytosol and tested for the basal tyrosine  phosphatase phosphatase activity in vitro on [32P]phospho-
band 3. Data are expressed as mean ± SD from 4 experiments performed in triplicate. Compared with the control, changes due 
to MP07-66 were statistically significant (*P ≤ 0.01). (D) Freshly isolated CLL cells were cultured in the absence (lanes 1 and 
5) or presence (lanes 2-4 and 6-8) of 8 µM MP07-66 supplemented without (lanes 1-2 and 5-6) or with 5 nM OA (lanes 3 and 
7) or 25 µM PTP I-I (lanes 4 and 8) for 0 and 6 h. Cells were then lysed and analyzed by Wb analysis with anti-pY380-procasp8 
and anti- pY307-PP2Ac antibodies. The blots were then stripped and reprobed with antibodies anti-procasp8 and anti-PP2Ac 
antibodies, respectively. The response to the antibodies and the enzyme activities of the samples shown in (B), (C) and (D) 
concerns the patient #28 as shown in the left-hand panel and are representative of all samples, whereas the results of pooled 
densitometric analysis (arbitrary units) of 16 patients from three independent experiments are histogrammed in the right-hand 
 63 
 
 
 
by annexin V–PI flow cytometry (Figure 26A). Nintedanib proved moderately 
effective at inducing apoptosis of CLL cells at 6 to 12 h, its efficacy being largely 
improved by the concomitant presence of MP07-66, which itself exhibited a pro-
apoptotic activity overlapping that of nintedanib when used as single agent. 
Similarly, co-
cultures of CLL 
cells with bone 
marrow 
mesenchymal 
stromal cells were 
treated as above 
with overlapping 
results (data not 
shown). 
Moreover, to 
explore how PP2A 
activation took part 
in the apoptotic 
process induced by 
MP07-66, CLL 
cells were treated 
with 15 µM 
nintedanib for 6 h 
in the absence or 
presence of okadaic acid (OA), a phosphatase inhibitor that is highly selective 
toward PP2A in the low nanomolar range (Fernandez et al., 2002). As expected, 5 
nM OA drastically reduced the apoptotic rate of CLL cells treated with MP07-66 
or the combination with nintedanib, but only to a lower extent with nintedanib 
Figure 26: Effect of the combined action of nintedanib and MP07-66 on CLL cell 
survival. The experiments described below were followed annexin V–PI flow cytometry to 
assess the effect of the treatments on the vitality of CLL cells. Quadrant analysis after flow 
cytometry was histogrammed and expressed as mean percentage of early and late apoptosis 
± SD from three separate experiments performed in triplicate. (A) Freshly isolated CLL 
cells were cultured in the absence or presence of either 15 µM nintedanib, 8 µM MP07-66, 
or a combination of 15 µM nintedanib and 8 µM MP07-66 at different time intervals. 
Compared with the effect of the compounds alone, changes due to the combination of the 
compounds were statistically significant (*P ≤ 0.01). (B) Freshly isolated CLL cells were 
cultured as described in (A) supplemented without or with 5 nM OA (rigth panels) for 6 h. 
Compared with the effect of the compounds alone or in combination, changes in the 
apoptotic rate due to OA were statistically significant (*P ≤ 0.01). The PP2A phosphatase 
activity performed on the same lysates is shown on the right-hand panel and reported as 
arbitrary units. Compared with the control, changes of the phosphatase activity due to OA 
were statistically significant (*P ≤ 0.01).  
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alone (Figure 26B, left-hand panel). Moreover, the PP2A activity assay performed 
by using a commercial PP2A assay kit on cell lysates of CLL cells treated as above 
showed a trend similar to that observed for the apoptotic rate (Figure 26B, right-
hand panel). Overall, these data corroborate the hypothesis that the inhibition of 
PP2A is central to CLL cell viability and that its activation is facilitated by the 
supportive action of SHP-1, as demonstrated by the effect generated by the 
simultaneous use of the respective activators.  
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Discussion 
In the present study, we show that nintedanib induces caspase-dependent apoptosis 
in CLL cells by directly activating the cytosolic pool of the tyrosine phosphatase 
SHP-1, which in turn dephosphorylates, and thus activates, pro-apoptotic key 
players such as procaspase 8 (procasp8) and PP2A.  
SHP-1 is a tyrosine phosphatase known to negatively regulate signalling in cells of 
hematopoietic lineage and in B cells modulating the response to antigens and 
contributing to the development of tolerance to self-antigens. In CLL, SHP-1 
undergoes multiple regulatory mechanisms leading to spatial and functional 
segregation, which is likely to play a relevant role in maintaining the cancer 
phenotype (Tibaldi et al., 2011). Phosphorylation of different residues in particular, 
especially at the C-terminus, significantly changes the activation status and 
localization of SHP-1, phospho-Y536 being typical of the activated pool bound to 
the plasma membrane co-receptor CD5, and phospho-S591 characterizing the 
inhibited pool of SHP-1 in the cytosol. This latter form appears to be one of the 
factors that sustains the aberrant Lyn-dependent tyrosine phosphorylation of 
countless proteins in the cytosol of CLL cells, which ultimately is key to the anti-
apoptotic signalling network of this disease (Contri et al., 2005; Zonta et al., 2014; 
Zonta et al., 2015). Here, we demonstrate that nintedanib, a small molecule known 
to act as triple angiokinase inhibitor within the low-nanomolar range (Hilberg et 
al., 2008), (Roth et al., 2009) and introduced into clinical practice for the 
management of pulmonary fibrosis and lung adenocarcinoma (McCormack, 2015), 
activates the cytosolic fraction of SHP-1 by circumventing pS591-dependent 
inhibition, as recently described in another cancer model (Tai et al., 2014). 
Significantly, in addition to leaving SHP-1 at the plasma membrane unaffected, as 
expected, nintedanib only marginally modifies tyrosine kinase activities even at 
micromolar concentrations in CLL cells. On the other hand, a dramatic drop in 
tyrosine phosphorylation occurs as a result of SHP-1 activation in the cytosol, and 
caspase-dependent apoptosis ensues, suggesting that the massive tyrosine 
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phosphorylation in CLL cells directly impinges on the function of factors that   
counteract the oncogenic machinery. Notably, although genetic ablation or 
pharmacologic inhibition of SHP-1 prevent the caspase-dependent apoptosis 
evoked by nintedanib, again supporting the hypothesis that the action of this drug 
is mediated by SHP-1, caspase-independent apoptosis was previously observed, 
which is in line with the role of the CD5-bound form of SHP-1 as a pro-survival 
agent in CLL (Tibaldi et al., 2011). Our findings clearly indicate that the 
partitioning of the two forms of SHP-1 is central to their differentiated function, at 
Figure 27. Working model of the positive feed-back signalling loop triggered by the combination of nintedanib and MP07-
66 resulting in CLL cell apoptosis. Phosphorylation-dependent inhibition of PP2A by the aberrant form of HSP90-bound Lyn 
is one of the key mechanisms that take part in the maintenance of the leukemic status of CLL cells. Under these conditions, 
the inability of PP2A to dephosphorylate and activate the tyrosine phosphatase SHP-1 supports the Lyn-mediated high level 
of cytosolic tyrosine phosphorylation, which ultimately sustains the oncogenic machinery in CLL cells. By directly activating 
SHP-1 and PP2A respectively, nintedanib and MP07-66 bring about the dephosphorylation of crucial players in the deranged 
signalling network of CLL, thus switching off pro-survivals and anti-apoptotic signals. Solid lines with arrows: 
phosphorylation; dotted lines with arrows: dephosphorylation. 
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the plasma membrane in an active form taking part in a signalosome that 
orchestrates survival signals, and in the cytosol remaining constrained in an 
inhibited conformation. We have shown that this condition prevents 
dephosphorylation of cytosolic Lyn targets with pro-apoptotic potential, as is the 
case of procasp8 and PP2A, the precursor of an effector caspase and a major 
serine/threonine phosphatase acting as a tumor suppressor respectively, 
substantially contributing to the suppression of their activity and ultimately to the 
survival of CLL cells. Procasp8 occurs as an inactive homodimer in CLL cells, the 
trigger for dimerization being the phosphorylation of Y380 due to the anomalous 
cytosolic activity of Lyn (Zonta et al., 2014). Here, nintedanib, via direct activation 
of cSHP-1, induces dephosphorylation, autocatalysis and activation of procasp8, 
which explains the caspase-dependent apoptosis observed. As to PP2A, Lyn-
mediated phosphorylation at Y307 of the catalytic subunit stabilizes its interaction 
with its physiologic inhibitor SET, thereby hampering the activity of the 
phosphatase. This in turn results in the persistent serine/threonine phosphorylation 
of PP2A substrates, including cSHP-1, and propagates pro-survival and anti-
apoptotic signals (Zonta et al., 2015). Conversely, nintedanib-activated cSHP-1 
dephosphorylates PP2A, facilitating the disruption of the PP2A/SET complex, with 
activation of PP2A itself and dephosphorylation of SHP-1 (Figure 26D), triggering 
the apoptotic response. This latter event is magnified by the combination of 
nintedanib with MP07-66 in that this latter compound directly interferes with the 
interaction between PP2A and SET (Zonta et al., 2015), further aiding in the 
reactivation of PP2A. In this scenario, nintedanib and the FTY720 analogue MP07-
66, direct activators of SHP-1 and PP2A respectively, appear to initiate a positive 
feedback signalling loop which opposes Lyn-mediated oncogenic signalling, thus 
promoting the dephosphorylation of crucial players in the deranged signalling 
architecture of CLL, switching off anti-apoptotic signals and unleashing cell death. 
In conclusion, our findings indicate that phosphatase activators may represent a 
new weapon in the armoury against this form of leukemia, especially in the light 
of the heterogeneity and the unavoidable progression of the disease as well as the 
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resistance to the front-line drugs currently in use, not to mention the adverse effects 
recently reported for the most promising second-line drugs (Brown, 2015; Barr et 
al 2016). 
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MATERIALS 
PARP polyclonal antibody was from Roche Applied Science (Mannheim, 
Germany). Anti-PP2A- C /ß, anti-p-PP2A-C /ß (Tyr307), anti-I2PP2A/SET 
and anti-caspase 3 antibodies, protein G PLUS-Agarose was from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Anti-pS591-SHP1 and anti-pY536 
SHP-1 were from ECM Biosciences (Versailles, KY, USA). Anti-procasp8, 
anti- phosphotyrosine (pY) and anti-SHP-1 antibodies, SHP-1 Inhibitor-I (PTP-
I-I), and Ser/Thr Phosphatase Assay Kit 1 (K-R-pT-I-R-R) were from Millipore-
Merck (Billerica, MA, USA). Anti- phospho-Tyr380 procasp8 (anti-p-casp8) 
antibody was from Abcam (Cambridge, UK). Anti-ß-actin antibody and okadaic 
acid were from Sigma-Aldrich (St Louis, MO, USA). Pierce ECL Western 
Blotting Substrate,  Protease inhibitor cocktail  were  from  Thermo  Fisher 
Scientific   (Strasbourg, 
France). The SHP-1 siRNA and negative control siRNA were provided by Santa 
Cruz Biotechnology (Santa Cruz, CA, catalog number sc-29478). [γ32P]ATP 
was from Perkin Elmer (Milan, Italy). Nintedanib was from Selleckchem 
(Houston, TX, USA). Caspase-8 Colorimetric Assay Kit was from Alexis 
Corporation, (Lausen, CH). 
 
METHODS 
Ethics Statement 
Written informed consents were obtained from all patients, prior to sample 
collection, according to the Declaration of Helsinki. The ethical approval for our 
study was obtained from the local ethical committee of “Regione Veneto on 
Chronic Lymphocytic Leukemia”. 
 
Patients, cell separation and culture conditions 
B cells from 37 CLL untreated patients were purified and cultured as previously 
described by our group, and subjected to the treatments described throughout the 
text. The patients’ relevant features are reported in Table 1. 
 72 
 
 
Cell lysis and subcellular fractionation 
For total lysates, normal and CLL cells (5 × 105 for each assay) were rapidly lysed 
in a buffer containing 62 mM Tris/HCl buffer, pH 6.8, containing 5% glycerol, 
0.5% SDS, and 0.5% β-mercaptoethanol. ; Trentin et al., 2008). For subcellular 
fractionation, CLL cells (15×106 for each assay) were disrupted and homogenized 
in isotonic buffer containing 50 mM Tris/HCl, pH 7.5, 0.25 M saccharose, 1 mM 
orthovanadate, and protease inhibitor cocktail (Boehringer) and centrifuged 10 min 
at 10,000g in order to separate the particulate fraction containing cell debris, nuclei, 
and other cellular particles. The supernatant was then subjected to 
ultracentrifugation for 1 h, performed at 105,000g, to separate cytosol from 
microsomes (particulate fraction) (Tibaldi et al., 2011). Protein concentration was 
determined by the Bradford method. 
 
Immunoprecipitation of SHP-1 
Cells were disrupted on ice by sonication (three cycles of 5 s at 22 Hz intervalled 
by 15 s) in isotonic buffer containing 1% NP-40, 20 mM Tris–HCl, pH 7.4, 250 
mM Sucrose, 2 mM EGTA, 150 mM NaCl, phosphatase and protease inhibitor 
cocktails. The lysates were centrifuged at 15 000 g for 10 min at 4 °C. The 
supernatants were immunoprecipitated for 2 h at 4 °C with the anti-SHP-1 antibody 
and immune complexes were recovered by incubation for 1 h with protein A-
Sepharose previously saturated with bovine serum albumine. The 
immunocomplexes were washed three times in 50 mMTris/HCl (pH 7.5), 0.05% 
NP-40, protease inhibitor cocktail and submitted to SHP-1 activity assays. 
 
SHP-1 activity assay 
SHP-1 activity was tested in SHP-1 immunoprecipitates in the presence of 0.3 μg 
of [32P]phospho-band 3 as a substrate as described in (Tibaldi et al., 2014). After 
10-min incubation at 30°C, the assays were stopped and subjected to SDS-PAGE. 
The extent of [32P]phospho-band 3 dephosphorylation was evaluated either by 
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analysis on a Packard Cyclone or by autoradiography and, after excision of the 
band 3, by liquid scintillation counting. 
 
[32P]-phospho band 3 preparation 
Band 3 was phosphorylated by incubating erythrocyte ghosts (15 μg) at 30°C 
with the tyrosine kinases Syk and Lyn in the presence of [γ32P]ATP as elsewhere 
described1. After 10-min incubation, the sample was centrifuged at 14,000 g and 
the pellet washed 3 times with 25 mM Tris, pH 8.0, 1 mM EDTA, 0.02% NaN3, 
10% glycerol, 10 mM β-mercaptoethanol, 10 mg/ml leupeptin, and 50 mM 
phenylmethylsulphonyl fluoride and then resuspended in the same buffer for the 
phosphatase activity assay. 
 
PP2A activity assays 
PP2A activity assays from samples undergoing the various treatments utilized 
throughout the study was measured by using the Malachite Green-based 
Phosphatase Assay Kit 1(K-R-pT-I-R-R) following the manufacturer’s 
instructions. 
 
Casp8 activity assay 
Casp8 activity from samples undergoing the various treatments utilized 
throughout the study was measured using a Caspase-8 Colorimetric Assay Kit 
according to the manufacturer’s instructions. 
 
Apoptosis assays 
CLL cells subjected to the various treatments applied throughout the study were 
collected forflow cytometric analysis. Ten thousand cells per sample were 
acquired with the use of BD FACS Diva software (version 7.0), and data were 
analyzed by plottingon an annexin V–PI logarithmic scattergram. 
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Western blotting 
Whole cell lysates and different cell fractions were run in 10% SDS-PAGE 
and transferred to nitrocellulose membranes. After 1 hour of treatment with 3% 
bovine serum albumine at room temperature, membranes were incubated with the 
appropriate antibodies overnight. Immunodetection was carried out with the ECL 
Western Blotting Substrate on the Kodak Image Station 4000mm Pro Digital 
System (Eastman Kodak, Rochester, NY, USA). Membranes, when required, 
were reprobed with other primary antibodies after stripping with 0.1 M glycine (pH   
2.5), 0.5 M NaCl, 0.1% Tween 20, 1% β-mercaptoethanol and 0.1% NaN3 for 2 x 
10 minutes. 
 
Cell transfection 
SiRNA transfection into CLL cells was performed using the AMAXA 
nucleofection system (AMAXA, Cologne, Germany). Briefly, cells (5x106) were 
resuspended in 100 μl of Nuclefector Solution, mixed with 300 nM of siRNA 
duplex (control or against SHP-1), and electroporated using program U-015 on 
AMAXA nucleofector device. Cells were then transferred to 37°C preheated 
medium and incubated for 48 h at 37°C, 5% CO2. 
 
In vitro tyrosine kinase assays 
To analyze cellular tyrosine kinase activity, CLL cells (4 × 105 for each assay) 
were lysed by adding 0.5% Triton X-100 and phosphatase and protease inhibitor 
cocktails in a 25-μl volume for 15 minutes. The tyrosine kinase activity was then 
tested in 50 μl of phosphorylation medium containing 50 mM Tris/HCl, pH 7.5, 
10 mM MnCl2, 30 μM [γ32P]ATP (Amersham Pharmacia Biotech) (specific 
activity 1,000 cpm/pmol), 200 μM sodium orthovanadate, and either 1 mg/ml 
random polymer polyGlu4Tyr (Sigma-Aldrich) or 200 μM cdc2(6–20) peptide 
used as exogenous substrates. After 10 minutes of incubation at 30°C, the reactions 
were stopped and the samples were loaded on SDS/P AGE . Substrate 32 P-
phosphorylation was quantified on a Packard Instant Imager. 
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Statistical analysis 
The data presented as mean ± SD were compared using one-way analysis of 
variance followed by Bonferroni post hoc test or Student’s t-test. A P-value ≤ 0.01 
was considered as statistically significant. All statistics were performed using 
GraphPad Prism (version 5) statistical software (GraphPad Software; San Diego, 
CA, USA).   
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